

**Session Title:** #168: Highlights of the Day II including Partners in Progress Award

**Session Type:** Highlights of the Day

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award  
*Kim Allyson Margolin, MD*
  - Highlights of the Day II including Partners in Progress Award  
*Douglas W. Blayney, MD*
  - Partners in Progress Award Recipient  
*Ellen V. Sigal, PhD*
  - Discussion: Genitourinary (Prostate) Cancer  
*Nicholas J. Vogelzang, MD*
  - Discussion: Gastrointestinal (Colorectal) Cancer  
*Howard S. Hochster, MD*
  - Discussion: Gynecologic Cancer  
*Claire F. Verschraegen, MD*
  - Discussion: Myeloma  
*Jean L. Harousseau, MD*
  - Discussion: Cancer Prevention/Epidemiology  
*Scott Michael Lippman, MD*
- 

**Session Title:** #16: Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100a

**Time:** 8:00 AM - 9:15 AM

- Overview of adjuvant clinical trials in stage II colon cancer - results, challenges, and confusion  
*Al Bowen Benson, III, MD*

- Prognostic and predictive molecular biomarkers in stage II colon cancer - current evidence and future perspective

*Sabine Tejpar, MD, PhD*

- Biomarker-driven treatment decisions in stage II colon cancer - making sense of what we know

*Neal J. Meropol, MD*

---

**Session Title:** #20: Cancer Survivors: A Challenge to Health Care Systems Worldwide

**Session Type:** Special Session

**Date:** Monday, June 7

**Location:** S100b

**Time:** 8:00 AM - 9:15 AM

- ASCO's Efforts to Promote Survivorship Care

*Douglas W. Blayney, MD*

- Follow-up and other health care needs of cancer survivors: how are different health care systems meeting the challenge?

*Eva Grunfeld, MD, D.Phil.*

- Life-threatening long-term effects after cancer: Who needs what follow-up?

*Sophie D. Fossa, MD*

- Challenges and opportunities in developing a cancer survivorship program in the context of current trends in oncology care

*Lawrence N. Shulman, MD*

- The Needs of Cancer Survivors

*Eliezer Robinson, MD*

---

**Session Title:** #29: Controversies in Adjuvant Systemic Treatment of Early-stage Breast Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** N Hall B1

**Time:** 8:00 AM - 9:15 AM

- Tailoring Adjuvant Therapy for HER2 Negative Breast Cancer

*Harold J. Burstein, MD, PhD*

- Small HER2-positive Tumors: When to Add Anti-HER2 Therapy?

*Ana M. Gonzalez-Angulo, MD, MSc*

- Is It Ok Not to Give Chemotherapy in Node-Positive Breast Cancer?

*Anthony Howell, MD*

---

**Session Title:** #41: Disparities in Cancer Care

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S404

**Time:** 8:00 AM - 9:15 AM

- Complex etiologies and strategies for reducing disparities in cancer care

*Beverly Moy, MD, MPH*

- Evolving U.S. population demographics and implications for disparities in cancer care

*Lisa A. Newman, MD, MPH*

- Cancer care in different contexts: Domestic and international perspectives

*Michael Silbermann, DMD, PhD*

---

**Session Title:** #54: Health Disparities in Lung Cancer: Race, Sex, and Genes

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 8:00 AM - 9:15 AM

- Molecular Epidemiology of Lung Cancer: Ancestry Matters

*Alex A. Adjei, MD, PhD*

- Molecular Genetic Variations Between Human Populations

*Patrick C. Ma, MD, MSc*

- Impact of Gender on Incidence, Behavior, and Therapy of Lung Cancer

*Nithya Ramnath, MD*

**Session Title:** #58: Impact of Health Literacy on Health Care, Decision Making and Consent

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E353

**Time:** 8:00 AM - 9:15 AM

- Impact of limited health literacy; assessing literacy and overcoming barriers to limited literacy in delivering health care

*Terry C Davis, PhD*

- overcoming literacy issues in obtaining informed consent

*Cathy A. Coyne, PhD*

- Decision making in breast and prostate cancer

*Angela Fagerlin, PhD*

---

**Session Title:** #87: Personalizing Therapeutic Approaches to Chronic Lymphocytic Leukemia

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E354a

**Time:** 8:00 AM - 9:15 AM

- Prognostic markers in CLL, do they matter?

*Sami N. Malek, MD*

- CLL in the elderly. How should it be treated?

*Clive Zent, MD*

- Evolving therapies for CLL

*Susan Mary O'Brien, MD*

---

**Session Title:** #97: The Biology and Treatment of Wilms Tumor

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S504

**Time:** 8:00 AM - 9:15 AM

- Wilms Tumor: Unsettled questions and controversies

*Jeffrey Dome, MD*

- Gene Expression Arrays: What have they taught us about Wilms tumor?

*Elizabeth Perlman, MD*

---

**Session Title:** #105: Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E354b

**Time:** 8:00 AM - 9:15 AM

- Management options for early stage seminoma and non-seminoma

*Christian K. Kollmannsberger, MD*

- Is RPLND still relevant?

*David Peter Wood, MD*

- Toxicity and survivorship in testicular cancer survivors. Should it modify what I do?

*George J. Bosl, MD*

---

**Session Title:** #106: Translocation-specific Sarcomas: Can Molecular Targets Translate to Therapeutics?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S406 (Vista Room)

**Time:** 8:00 AM - 9:15 AM

- Target genes of chimeric transcription factors in pediatric sarcomas: a source of potential therapeutic targets

*Marc Ladanyi, MD*

- Targeting protein products of sarcoma specific translocations with small molecules

*Jeffrey Toretsky, MD*

- IGF1R targeting of translocation-associated sarcomas

*Lee J. Helman, MD*

**Session Title:** #114: Contract Negotiation for Your First Job

**Session Type:** Meet the Professor Session

**Date:** Monday, June 7

**Location:** E451b

**Time:** 8:00 AM - 9:15 AM

- Contract Negotiation for Your First Job

*Jamie H. Von Roenn, MD*

**Session Title:** #139: The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 8:00 AM - 9:15 AM

- Diagnosis and Management of the Renal Mass

*Steven Campbell, MD, PhD*

- Management of Non-clear Cell Histology

*Przemyslaw Twardowski, MD*

- Optimal Management of Toxicities Related to Targeted Agents

*Tim Eisen, PhD, FRCP*

**Session Title:** #180: Genitourinary (Prostate) Cancer

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E450a

**Time:** 8:00 AM - 12:00 PM

- Genitourinary (Prostate) Cancer

*Daniel W Lin*

- Genitourinary (Prostate) Cancer

*Andrea Lynne Harzstark, MD*

1 #4544-A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis.

2 #4545-Bone scan "flare" in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

*Shreya K. Shah*

3 #4546-Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.

*Aseem Anand*

4 #4547-Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC).

*Eleni Efstathiou*

5 #4548-Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity.

*Tomasz M. Beer, MD, FACP*

6 #4549-The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized trials.

*Emmanuel S. Antonarakis, MD*

- Discussion: Biomarkers of response in prostate cancer

*Johann Sebastian De Bono, MD, PhD*

7 #4550-Predictors of outcome and subgroup results from the integrated analysis of sipuleucel- $\tau$ ; trials in metastatic castration-resistant prostate cancer.

*Celestia S. Higano, MD*

8 #4551-Persistence of immunotherapy survival effects of sipuleucel- $\tau$ ; and relationship to postrandomization docetaxel use in phase III studies.

*Daniel Peter Petrylak*

9 #4552-Correlation between product parameters and overall survival in three trials of sipuleucel- $\tau$ ; , an autologous active cellular immunotherapy for the treatment of prostate cancer.

*Frances P Stewart*

- Discussion: Can we predict who will respond to immunotherapy?

*Robert Dreicer, MD*

10 #4553-Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).

*Paul L. De Souza*

11 #4554-Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts).

*Daniel Keizman*

12 #4555-Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy.

*Mark T. Fleming*

13 #4556-ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

*Mark N. Stein*

14 #4557-Association between genetic polymorphisms in *SLCO1B3* gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC).

*Mary-Ellen Taplin, MD*

- Discussion: Novel therapies and response predictors for CRPC

*Celestia S. Higano, MD*

15 #4558-Dynamics of bone mineral density during intermittent androgen deprivation for men with biochemical recurrence of prostate cancer.

*Evan Y. Yu, MD*

16 #4559-Fractures and post-fracture mortality in elderly prostate cancer (PC) patients receiving androgen deprivation therapy (ADT) in the United States.

*Karynsa Cetin*

17 #4560-The effect of ADT on objective cognitive performance and self-reported cognitive function in men with prostate cancer.

*Shireen Marzouk*

- Discussion: The impact of ADT on bone and brain

*Matthew Raymond Smith, MD, PhD*

18 #4561-The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

*David G Bostwick*

19 #4562-Effect of inflammation on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

*Otis W. Brawley*

20 #4563-Positive biopsy (bx) rates for prostate cancer (PCA) based on prostate specific antigen (PSA) grouping in a large cancer screening trial: Prostate, lung, colorectal, and ovarian cancer screening trial (PLCO).

*Douglas Reding*

21 #4564-Cancer genetics-guided discovery of serum biomarker signatures for prostate cancer.

*Silke Gillissen*

22 #4565-Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer.

*E. David Crawford*

- Discussion: Risk identification, chemoprevention, surveillance and neoadjuvant therapy in early prostate cancer

*Joel B. Nelson, MD*

---

**Session Title:** #186: Lung Cancer - Metastatic

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E450b

**Time:** 8:00 AM - 12:00 PM

- Lung Cancer - Metastatic

*Shirish M. Gadgeel, MD*

- Lung Cancer - Metastatic

*Taofeek Kunle Owonikoko, MD*

1 #7512-Use of ERCC1 expression levels in circulating tumor cells to predict response to platinum-based chemotherapy in patients with non-small cell lung cancer.

*Andreas Claudius Hoffmann*

2 #7513-Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy.

*David R. Gandara*

3 #7514-Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

*Rafael Rosell*

5 #7516-Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.

*Bruce E. Johnson, MD*

6 #7517-Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).

*Lecia Sequist, MD*

- Discussion: Biomarkers

*Michael J. Kelley, MD*

7 #7518-A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03).

*Rabab Mohamed Gaafar*

8 #7519-Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

*Lampros Vamvakas*

9 #7520-Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI).

*Geoffrey Raymond Oxnard*

10 #7521^~A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

*Chih-Hsin Yang*

11 #7522-Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504).

*Suresh S. Ramalingam, MD*

12 #LBA7523-Efficacy and safety of PF299804 versus (v) erlotinib (E): a global, randomized phase (P) 2 trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).

*Michael J. Boyer*

13 #7524-Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).

*Natasha B. Leigh*

- Discussion: New approaches in EGFR targeted therapy

*Karen L. Reckamp, MD, MS*

14 #7525-Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

*Jin Soo Lee*

15 #7526-Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

*Fairooz F. Kabbinavar*

16 #7527-A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of paclitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC).

*Baohui Han*

17 #7528-Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

*George R Blumenschein, Jr, MD*

- Discussion: Anti-angiogenic agents

*Silvia Novello, MD, PhD*

19 #7530-Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605).

*Hiroshige Yoshioka*

20 #7531-Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

*Thomas James Lynch*

22 #7533-Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC).

*Primo Lara, MD*

23 #7534-A randomized phase II study of paclitaxel (P) and carboplatin (C) &plusmn; bevacizumab (B) &plusmn; dulanermin (D) in non-small cell lung cancer (NSCLC).

*Fiona Hellen Blackhall*

24 #7535-Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).

*Christos Stelios Karapetis*

- Discussion: New agents

*Suresh S. Ramalingam, MD*

**Session Title:** #188: Melanoma/Skin Cancers

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** S403

**Time:** 8:00 AM - 12:00 PM

- Melanoma/Skin Cancers

*Gregory A. Daniels, MD, PhD*

- Melanoma/Skin Cancers

*Ravi K. Amaravadi, MD*

1 #8513-Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008.

*Jeffrey Alan Sosman, MD*

2 #8514-Early ultrasound criteria drive sensitivity for detection of sentinel node metastases in melanoma patients: A prospective study in 800 patients.

*Christiane A. Voit*

3 #8515-Report card for compliance with NCCN guidelines in the surgical management of cutaneous melanoma across the United States: Time for remedial classes?

*Nabil Wasif*

4 #8516-Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study.

*Michael B. Atkins, MD*

5 #8517-Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008.

*Vernon K Sondak, MD*

- Discussion

*Julie R. Lange, MD*

6 #8518-Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers.

*Lore Decoster, MD*

7 #8519^--A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).

*Richard D. Carvajal*

9 #8521-First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).

*Reinhard Dummer*

10 #8522-Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma.

*Roger Mouawad*

- Discussion

*David F. McDermott, MD*

11 #8523-Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

*Donald P. Lawrence*

12 #8524-Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

*Ahmad A. Tarhini*

13 #8525-Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

*Omid Hamid*

14 #8526-Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.

*Axel Hauschild*

- Discussion

*Henry B. Koon, MD*

15 #8527-A phase II study of imatinib for advanced melanoma patients with KIT aberrations.

*Jun Guo, MD, PhD*

16 #8528-Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).

*Lynn G. Feun*

17 #8529-Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.

*Grant A. McArthur, PhD*

18 #8530-Phase II study of vorinostat in patients with advanced melanoma.

*Naomi B. Haas*

19 #8531-Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.

*Wen-Jen Hwu*

20 #8532-A phase I/II trial of DTIC and dasatinib in metastatic melanoma.

*Alain Patrick Algazi*

- Discussion

*Anna C. Pavlick, MD*

---

**Session Title:** #197: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

**Session Type:** General Poster Session

**Date:** Monday, June 7

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

1A #2539-A phase I study of CD40 agonist monoclonal antibody (CP-870, 893) with gemcitabine in pancreatic cancer.

*Gregory Lawrence Beatty*

1B #2540-Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.

*David S. Hong, MD*

1C #2541-A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

*Daniel D. Von Hoff, MD*

1D #2542-Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with adjuvant HER2/neu-based peptide vaccines.

*Kevin S. Clive*

1E #2543-PET imaging of [11C]docetaxel uptake and tumor perfusion in lung cancer.

*Astrid A. van der Veldt*

1F #2544-Effect of a novel recombinant alphaviral vector on tolerance to self-antigen in the setting of elevated regulatory T cells.

*Michael Morse*

1G #2545-Phase I study of vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI organ dysfunction working group (ODWG) study (NCI #8057).

*Merrill J. Egorin, MD*

1H #2546-A phase I/II study of intravenous Rexin-G and Reximmune-C for cancer immunotherapy: The GeneVieve protocol.

*Jorge G. Ignacio*

2A #2547-Phase I trial of BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors.

*Laura Quan Man Chow, MD, FRCPC*

2B #2548-Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.

*Martin David Forster*

2C #2549-New approach for assessment of potential ethnic differences in parallel phase I/II studies in the United States and Asia.

*Toshihiko Doi*

2D #2550-Overall survival (OS) analysis of a phase I trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

*Ravi Amrit Madan*

2E #2551-The trifunctional antibody catumaxomab: Correlation between immunological response and clinical outcome—New analysis of a pivotal phase II/III study.

*Marion Gabriele Ott*

2F #2552-A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.

*Udai Banerji*

2G #2553-Pharmacokinetics (PK) of PF-562271, a focal adhesion kinase (FAK) inhibitor, and its effect on CYP3A in patients with advanced nonhematologic malignancies.

*Huiping Xu*

2H #2554-Final results of a phase Ib trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, in combination with gemcitabine (G) or docetaxel (D) in patients with advanced solid tumors.

*Michael B. Jameson*

3A #2555-CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes.

*Arvin Yang, MD, PhD*

3B #2556-ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.

*John Sarantopoulos*

3C #2557-Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors.

*Johanna Wilmink*

3D #2558-A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of non-childbearing potential.

*Bert L. Lum, PharmD*

3E #2559-NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors.

*Patrick J. Mansky, MD*

3F #2560-A phase I study of sonopizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors.

*Michael S. Gordon*

3G #2561-Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of aryl-hydrocarbon receptor-mediated aminoflavone prodrug AFP464 in advanced solid tumors.

*Christophe Massard*

3H #2562-A phase I safety and tolerability study of vorinostat (V) in combination with sorafenib (S) in patients with advanced solid tumors, with exploration of two tumor-type specific expanded cohorts at the recommended phase II dose (renal and non-small cell lung carcinoma).

*A. Dasari*

4A #2563-A phase I study of bortezomib (BTZ) and temozolomide (TMZ) in patients with advanced solid tumors.

*Jana Portnow*

4B #2564-Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors.

*Alice C. Fan*

4C #2565-Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations.

*Guy T. Clifton*

4D #2566-Pharmacology of high-dose methotrexate in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG #20 trial.

*Andres J. Ferreri*

4E #2567-Effect of TGF- $\beta$ 1 expressed on tumor-derived exosomes on survival and function of regulatory T cells.

*Hideya Onishi, DrPH, MD*

4F #2568-Factors of interindividual hematopoietic toxicity of carboplatin.

*Etienne Chatelut*

4G #2569-Effect of prophylactic administration of recombinant human thrombopoietin on chemotherapy-induced severe thrombocytopenia in patients with advanced non-small cell lung cancer: A prospective self-control clinic study.

*Shun Lu*

4H #2570-A phase I study of ARRY-520 in solid tumors.

*Priscila H. B. Goncalves*

5A #2571-A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD).

*Stephen Shibata*

5B #2572-Phase I, pharmacokinetic study of temsirolimus in combination with nelfinavir in patients with solid tumors.

*Wiete Kromdijk*

5C #2573-Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer.

*Walter M. Fiedler*

5D #2574-Clinical outcome of first-line melanoma patients who continue tremelimumab in spite of early disease progression.

*Diane I. Healey*

5E #2575-Early disease progression in a phase I study of bortezomib (B), cetuximab (C), and intensity-modulated radiation therapy (IMRT) for squamous cell carcinoma of the head and neck (SCCHN).

*Carter Van Waes*

5F #2576-Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.

*Glen J. Weiss*

5G #2577-Genetic polymorphisms of metabolizing enzymes and transporters correlate with pharmacokinetics (PK) and pharmacodynamics (PD) of amrubicin.

*Yoshinori Makino*

5H #2578-Identification of novel prostate cancer-associated antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade.

*Lawrence Fong*

6A #2579-Clinical and immunological responses to a DNA fusion vaccine in patients with carcinoembryonic antigen-expressing tumors: A Cancer Research UK phase I/II study.

*Christian H.H Ottensmeier*

6B #2580-Phase I study evaluating the safety, tolerability, and pharmacokinetics (PK) of HGS1029, a small-molecule inhibitor of apoptosis protein (IAP), in patients (pts) with advanced solid tumors.

*S. Gail Eckhardt, MD*

6C #2581-Histopathologic and immunohistochemical findings of skin rash to HER1 and HER1/2 inhibitors during anticancer therapy.

*Beatrice Nardone*

6D #2582-Eribulin mesylate pharmacokinetics in patients with hepatic impairment.

*Petronella Witteveen*

6E #2583-PIK3CA, KRAS, and BRAF mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

*Filip Janku*

6F #2584-Pharmacokinetics (PK) of oxaliplatin (OX) after intraperitoneal (IP) and intravenous (IV) administration in patients with gynecological malignancies.

*Austin J. Combest*

6G #2585-Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma.

*Ling-Zhi Wang*

6H #2586-Impact of antidiabetic agents on the survival of subjects with colorectal cancer (CRC).

*Thandiwe C. Gray*

7A #2587-Correlation of immune responses with survival in a randomized phase II study investigating multi-peptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC).

*Harpreet Singh*

7B #2588-Improving patient selection for oncology phase &Iota; trials: Predictors of 90-day mortality and overall survival.

*Nicole Grace Chau, MD, FRCPC*

7C #2589-Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.

*Umang Swami, MBBS*

7D #2590-Phase I/II study of BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma.

*David A. Reardon*

7E #2591-A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.

*Ezra E. W. Cohen, MD, FRCPC*

7F #2592-A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-small cell lung cancer (NSCLC).

*Aradeep Chatterjee, MD*

7G #2593-Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: Response, survival, and prognostic factors.

*Marine Gilabert*

7H #2594-Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors.

*Martin Zweifel*

8A #2595-Phase I trial of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced malignancies.

*Ernesto Bustinza-Linares*

8B #2596-Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.

*Weiwei Tan*

8C #2597-Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor.

*Naifa Busaidy*

8D #2598-Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).

*Mark Kozloff*

8E #2599-A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.

*Lulama Rhoda Molife*

8F #2600-Evaluation of poxviruses targeting the tumor microenvironment for cancer therapy.

*Dae Won Kim*

8G #2601-A comparison of the Cockcroft-Gault (CG) and the modification of diet in renal disease (MDRD) equations for estimating renal function and guiding dose adjustment of oncology-related drugs.

*Joseph A. Grillo, PharmD*

8H #2602-A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors.

*Amir Mortazavi*

9A #2603-Phase I study of proteasome inhibitor bortezomib (B) concurrent with re-irradiation therapy (re-RT) for recurrent squamous cell carcinoma of the head and neck (SCCHN).

*John Charles Morris*

9B #2604-Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience.

*Jennifer J. Wheler*

9C #2605-A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.

*Shivaani Kummar*

9D #2606-Single-nucleotide polymorphisms (SNPs) of CYP19A1 and plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.

*Gianluigi Lunardi*

9E #2607-Phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): First-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent administered on days 1, 4, 8, and 11 of a 21-day cycle.

*Maja De Jonge*

9F #2608-Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results.

*Bijal Dinesh Shah*

9G #2609-Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma.

*Margaret A. Marshall*

9H #2610-Phase I trial of dasatinib (D) and lapatinib (L).

*Charles Erlichman*

10A #2611-Trabectedin (AP 12009) in the treatment of patients with advanced tumors: Completion of dose-escalation and first efficacy data.

*Helmut Oettle*

10B #2612-Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors.

*Margaret von Mehren, MD*

10C #2613-A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941.

*Richard D. Baird, MBBS, MRCP*

**Session Title:** #198: Developmental Therapeutics - Experimental Therapeutics**Session Type:** General Poster Session**Date:** Monday, June 7**Location:** S Hall A2**Time:** 8:00 AM - 12:00 PM

10D #3034-Phase I study of PF-03446962, a fully human mab against ALK 1, a TGF $\beta$ ; receptor involved in tumor angiogenesis.

*Laura Williams Goff*

10E #3035-Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.

*Toshio Shimizu*

10F #3036-French, multicentric, prospective study of dynamic contrast-enhanced ultrasound (DCE-US) for the evaluation of antiangiogenic treatments in 400 patients.

*Nathalie Lassau*

10G #3037-Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer.

*Michael B. Bass*

10H #3038-Final results from a phase I study of TRC093 (humanized anti-cleaved collagen antibody) in patients with solid cancer.

*Francisco Robert*

11A #3039-Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

*Herbert Hurwitz*

11B #3040-Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies.

*Surena F. Matin*

11F #3041-Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer.

*Gary K. Schwartz, MD*

11G #3042-Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

*Jared Gollob*

11H #3043-Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors.

12B #3045-Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

*Marlies HG Langenberg*

12F #3046-A phase I study of sunitinib malate (S) and gemcitabine (G) in solid tumors.

*Smitha S. Krishnamurthi*

12G #3047-Phase I clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors.

*A. Fasolo*

12H #3048-Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC).

*Ben Suttle*

13A #3049-Direct in vivo evaluation of tumor VEGFR in response to treatment with pazopanib: A novel molecular imaging study.

*Susanta K. Sarkar*

13B #3050-Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI.

*Robert Jeraj*

13C #3051-Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at 3 tesla (T).

*Ingrid Desar*

13D #3052-Predictive and mechanistic factors of tyrosine kinase inhibitor (TKI) induced macrocytosis.

*Paul Hamberg*

13E #3053-Extended linifanib therapy in patients with advanced solid tumors in a phase I trial.

*Boon C. Goh*

13F #3054-A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation.

*Geoffrey Chong*

13G #3055-Phase II trial of dose-escalated sorafenib in advanced solid tumors.

*Thomas John Semrad*

13H #3056-Association of VEGF feedback production in bevacizumab therapy with systemic response.

*Patrick Starlinger*

14A #3057-A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.

*E. Angevin*

14B #3058-A phase I dose-escalation study of IMGN388 in patients with solid tumors.

*Dana Shelton Thompson*

14C #3059-A phase I study of two different schedules of nab-paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumors.

*Anthony B. El-Khoueiry, MD*

14D #3060-Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer.

*Dennis J. Slamon, MD, PhD*

14E #3061-Final analysis of a phase I single dose escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.

*Thierry Gil*

14F #3062-Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

*Nicoletta Brega*

14G #3063-Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors.

*Rastislav Bahleda*

14H #3064-A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors.

*Adil Daud*

15A #3065-Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration.

*Sara Cresta*

15B #3066-Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.

*Peter J. Rosen*

15C #3067-A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

*Suzanne Leijen*

15D #3068-Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclizolamine in relapsed/refractory Hodgkin lymphoma (HL).

*Carmelo Carlo-Stella*

15E #3069-Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors.

*Geoffrey Shapiro*

15F #3070-A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.

*Cristian Moldovan*

15G #3071-First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies.

*Eve T. Rodler*

15H #3072-Phase I dose-finding study of BN80927 as an intravenous infusion every 21 days in patients with advanced malignant solid tumors.

*Thierry Lesimple*

16A #3073-Emergence of oral targeted agents in early clinical development: Experience at M. D. Anderson Cancer Center (MDACC) Clinical and Translational Research Center (CTRC).

*Kirk Salvatore Culotta*

16B #3074-Application of multinomial (MN) phase II designs in trials of targeted agents.

*Rahima Jamal*

16C #3075-Novel strategy to identify drugs that delay relapse.

*Marcia Hall*

16D #3076-Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1 $\alpha$ ;

*Raoul Tibes*

16E #3077-Phase I trial of OGX-427, a 2'-methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.

*Sebastien J. Hotte*

16F #3078-A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.

*Anne M. Traynor, MD*

16G #3079-A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma.

*Saoirse Dolly*

16H #3080-A phase I/II study of oncolytic reovirus plus carboplatin/paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN).

*Eleni M Karapanagiotou*

17A #3081-Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.

*Suzanne Fields Jones*

17B #3082-A phase I study of EC0225 administered weeks 1 and 2 of a 4-week cycle.

*Sunil Sharma*

17C #3083-A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.

*James M. Cleary*

17D #3084-Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study.

*Robert Dreicer, MD*

17E #3085-A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma.

*Phioanh Leia Nghiemphu*

17F #3086-Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603).

*Myrna Rachel Rosenfeld, MD, PhD*

17G #3087-First-in-human study evaluating safety and pharmacokinetics of endoxifen, a potent estrogen-receptor antagonist for breast cancer.

*Ateeq Ahmad*

17H #3088-A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer.

*Wael A. Harb*

18A #3089-Final results from a phase I, dose escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.

*Antonio Jimeno*

18B #3090-Temsirolimus (TEM) in endometrial cancer: Predictors of response and progression.

*Rachel Anne Goodwin*

18C #3091-Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response.

*Anitha S Nallari*

18D #3092-Gene expression analysis in human hair bulbs as a potential pharmacodynamic readout in the LDE225 clinical program.

*Kristine Rose*

18E #3093-Sensitive detection of gamma-H2AX induction as a pharmacodynamic marker for profiling patients with cancer treated with topotecan.

*Darren O. Davis*

18F #3094-Characterization of proliferative rebound during drug holiday by FLT-PET imaging in patients treated with sunitinib (SU).

*Michael Roger Harrison*

18G #3095-Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors.

*Xiaoning Wang*

18H #3096-Pharmacokinetic, pharmacodynamic, and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer.

*Akihito Kubo*

19A #3097-Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.

*Vered Stearns, MD*

19B #3098-Pharmacogenetic factors predicting the need for a higher dose of imatinib.

*Heinz-Josef Klumpen*

19C #3099-DPYD single nucleotide polymorphisms (SNPs) and haplotypes in patients (pts) with metastatic colorectal cancer and toxicity of capecitabine.

*Maarten J. Deenen, PharmD*

19D #3100-Relationship of *HLA-DQA1\*0201* and lapatinib-induced hepatotoxicity in women with advanced breast cancer.

*Colin F Spraggs*

19E #3101-The contribution of *UGT1A* and *ABCB1* to irinotecan-induced toxicity: A prospective pharmacogenetic study of patients with metastatic colorectal cancer.

*Eric Levesque*

19F #3102-Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.

*Sant P. Chawla*

19G #3103-Phase I study of AV-412, a novel, irreversible EGFR inhibitor, administered intermittently in patients with advanced solid tumors.

*Karen Kelly*

19H #3104-Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.

*Jayesh Desai*

20A #3105-A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma.

*David C. Smith*

20B #3106-Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (Study 265-101).

*Michel A. Drouin*

20C #3107-Evaluation of serum protein mass spectrometry technology to identify NSCLC patients with tumor response to gefitinib.

*Yi Pei*

20D #3108-A phase I study of oral administration of MGCD265 in patients with advanced malignancies (Study 265-102).

*Elisabeth I. Heath*

---

**Session Title:** #221: Paths for Clinical Development of PI3K Inhibition

**Session Type:** Clinical Science Symposium

**Date:** Monday, June 7

**Location:** E Arie Crown Theater

**Time:** 8:00 AM - 9:30 AM

- Paths for Clinical Development of PI3K Inhibition

*A. Dimitrios Colevas, MD*

- Paths for Clinical Development of PI3K Inhibition

*Pasi A. Janne, MD, PhD*

- Discussion

*Neal Rosen, MD, PhD*

- #3003-A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

*Jose Baselga, MD*

- #3004-A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

*Gerald Edelman*

- #3005-First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

*Howard Burris*

- Discussion: Next steps in clinical development of PI3K inhibitors?

*Carlos L. Arteaga, MD*

---

**Session Title:** #62: Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S406 (Vista Room)

**Time:** 9:30 AM - 10:45 AM

- Review of standard and emerging therapies for localized and advanced urothelial cancer

*David I. Quinn, PhD, FRACP, MBBS*

- Personalizing therapy for urothelial cancer: clinical and molecular biomarkers

*Jonathan E. Rosenberg, MD*

- How to overcome barriers to the adoption of neoadjuvant therapy for locally advanced urothelial cancer

*Ralph deVere White, PhD*

---

**Session Title:** #144: Breast Cancer - Local-Regional and Adjuvant Therapy

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** N Hall B1

**Time:** 9:30 AM - 12:30 PM

- Breast Cancer - Local-Regional and Adjuvant Therapy  
*Seema Ahsan Khan, MD, FACS, MPH*
- Breast Cancer - Local-Regional and Adjuvant Therapy  
*Rita Nanda, MD*
- #CRA504-ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer.  
*Richard Cote*
- #LBA505-Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients  
  
*David N. Krag*
- #CRA506-ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node.  
*Armando E. Giuliano*
- #507-Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer.  
*Kevin S. Hughes, MD, FACS*
- Discussion  
*William C. Wood, MD*
- #508-Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial.  
*Stephen K. L. Chia, MD*
- #509-Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.  
*Gong Tang, PhD*
- #510-Pharmacogenetics of tamoxifen in relation to disease-free survival in a dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.  
*Vincent O. Dezentje*
- Discussion  
*Angelo Di Leo, MD, PhD*

- #511-Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer.

*Kathy S. Albain*

- #512-Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial.

*Georg Pfeiler, MD*

- Discussion

*Pamela Jean Goodwin, MD*

---

**Session Title:** #156: Health Services Research

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** S404

**Time:** 9:30 AM - 12:30 PM

- Health Services Research

*Elena B. Elkin, PhD*

- Health Services Research

*Sarah T. Hawley, MD, PhD*

- #6000-Changes over time in quality of psychosocial care: Results from the Quality Oncology Practice Initiative (QOPI).

*Paul B. Jacobsen*

- #6001-Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials.

*Steven K Cheng*

- #6002-Assessment of performance measures for patients with the myelodysplastic syndrome (MDS) in the United States.

*Gregory Alan Abel*

- Discussion: Implementing performance measures to improve patient care

*Steven J. Katz, MD*

- #6003-Comparison of SEER registry data to patient self-report.

*Reshma Jagsi*

- #6004-State-wide application of breast and colon cancer quality measures (QMs) using linked claims and registry data.

*Stephen B. Edge, MD*

- #6005-Comorbidity severity and long-term mortality in men with early-stage prostate cancer.

*Timothy J. Daskivich*

- #6006-Development of a performance status prediction model for use in administrative data analyses.

*Amy J. Davidoff*

- #6007-Adoption of CT-based simulation and outcomes following radiation for stage III non-small cell lung cancer.

*Aileen B. Chen*

- #6008-Factors influencing the uptake of the human papillomavirus (HPV) vaccine to prevent cervical cancer (CC).

*Jennifer YiChun Lai, MD, MPH*

- Discussion: Diffusion of therapeutic and preventive innovations

*Joseph Lipscomb, PhD*

---

**Session Title:** #157: Leukemia, Myelodysplasia, and Transplantation

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** E354b

**Time:** 9:30 AM - 12:30 PM

- Leukemia, Myelodysplasia, and Transplantation

*William G. Blum, MD*

- Leukemia, Myelodysplasia, and Transplantation

*Jessica K. Altman, MD*

- #LBA6500-Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.

*Hagop Kantarjian*

- #6501-Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.

*Richard A. Larson*

- #6502-Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).

*Jorge E. Cortes*

- Discussion: Chronic Phase CML- Beyond Imatinib?

*Michael J. Mauro, MD*

- #6503-Time-dependent decision analysis: Stable disease in azacitidine (AZA) treated patients (pts) with higher-risk MDS.

*Steven Gore*

- #6504-A randomized study of two dose levels of intravenous (IV) clofarabine (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS).

*Elias Jabbour*

- #6505-Improvement of leukemia-free survival (LFS) and reduction of relapse incidence by allogeneic stem cell transplantation (SCT) in elderly patients (pts) with AML irrespective of the FLT3-ITD and nrm status except nrm+/flt3(ITD)-.

*Dietger Niederwieser*

- Discussion: High risk MDS and AML in the elderly. Are we making progress?

*Jeffrey E. Lancet, MD*

- #6506-Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).

*Deborah A. Thomas*

- #6507-Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).

*Susan Mary O'Brien, MD*

- #6508-A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia.

*Xavier Badoux*

**Session Title:** #165: Pediatric Oncology II

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** S504

**Time:** 9:30 AM - 12:30 PM

- Pediatric Oncology II

*Gregory T. Armstrong, MD, MSCE*

- Pediatric Oncology II

*Tara O. Henderson, MD, MPH*

- #9512-Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: A Children's Oncology Group study.

*Javier G. Blanco*

- #9513-Late cardiac status in long-term survivors of childhood high-risk ALL 8 years after continuous or bolus infusion of doxorubicin: The DFCI Childhood ALL 91-01 randomized trial.

*Steven Lipshultz*

- #9514-Chronic medical conditions, health status, and health care practices at 25 years in 5-year survivors of Wilms tumor: A report from the Childhood Cancer Survivor Study.

*Amanda M. Termuhlen*

- Discussion: Cardiac status in survivors of pediatric cancer

*Melissa M. Hudson, MD*

- #9515-Childhood cancer: Do females experience more acute toxicities than males? A Report from the Children's Oncology Group

*Kathleen Ann Meeske*

- #9516-MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study.

*Gregory A Yanik*

- #9517-Racial and ethnic disparities in disease presentation and survival among children with neuroblastoma (NBL): A Children's Oncology Group (COG) study.

*Susan Lerner Cohn, MD*

- #9518-Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.

*Wendy B. London, PhD*

- Discussion: Prognostic Variables in Neuroblastoma

*Andrew Pearson, MD, FRCP*

- #9519-Multiple subsequent neoplasms in the childhood cancer survivor study (CCSS) cohort.

*Gregory T. Armstrong, MD, MSCE*

- #9520-Gastrointestinal malignancies as a subsequent malignant neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

*Tara O. Henderson, MD, MPH*

- Discussion

*Flora E. Van Leeuwen, PhD*

**Session Title:** #50: Family Members and Caretakers: Helping the Family and Helping the Family Help the Patient

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E353

**Time:** 9:45 AM - 11:00 AM

- Family and caregiver needs over the course of the cancer

*Barbara Given, PhD, RN, FAAN*

- Partner-based interventions to enhance coping and pain management, and reduce distress in individuals with cancer

*Francis J. Keefe, PhD*

- Capitalizing on the Mother-Daughter bond to promote primary and tertiary prevention. Diet and Exercise Interventions to Promote Weight Loss and Improve Diet and Exercise Behaviors among Overweight Women with Breast Cancer and their Daughters

*Wendy Demark-Wahnefried, MD*

---

**Session Title:** #77: Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 9:45 AM - 11:00 AM

- (Neo)adjuvant chemotherapy in the management of localized esophagogastric carcinoma.

*Peter C. Enzinger, MD*

- Neoadjuvant chemoradiation in the management of localized esophagogastric carcinoma.

*Mohan Suntharalingam, MD*

- Implications for surgery following chemotherapy or chemoradiation.

*Cliff P. Connery, MD*

---

**Session Title:** #93: Seminal Advances in Lung Cancer Research 2010: Translational and Clinical

**Session Type:** Education Session

**Date:** Monday, June 7

- Translational Advances in Lung Cancer  
*Ravi Salgia, MD, PhD*
  - Clinical Advances in Lung Cancer  
*Ramaswamy Govindan, MD*
  - Perspectives on Recent Advances in Lung Cancer  
*Jeffrey Crawford, MD*
- 

**Session Title:** #102: Improving the Value of Cancer Clinical Trials: Recommendations from the Institute of Medicine and the NCI's Clinical Trials and Translational Research Advisory Committee

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100a

**Time:** 9:45 AM - 11:30 AM

- Obstacles to clinical trial development and implementation  
*David M. Dilts, PhD, MBA*
  - Streamlining the extramural clinical trials system  
*James H. Doroshow, MD*
  - Recommendations by the IOM on Reinvigorating Cooperative Group Clinical Trials  
*John Mendelsohn, MD*
  - The Role of Cooperative Groups in Comparative Effectiveness Research  
*Richard L. Schilsky, MD*
- 

**Session Title:** #113: Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor

**Session Type:** Meet the Professor Session

**Date:** Monday, June 7

**Location:** E451b

**Time:** 9:45 AM - 11:00 AM

- Clinical Research Mentorships: How to Find a Mentor, How to Be a Mentor  
*Evanthia Galanis, MD*

**Session Title:** #141: Treatment of Barrett's Esophagus to Prevent Esophageal Cancer

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 9:45 AM - 11:00 AM

- Esophageal resection for high-grade dysplasia and superficial cancer  
*Hiran C. Fernando, MD, MBBS*
- Multimodality approaches for endoscopic ablation of Barrett's esophagus  
*Kenneth K Wang, MD*
- Risk stratification, chemoprevention and early detection in Barrett's esophagus  
*Brian J. Reid, MD, PhD*

**Session Title:** #224: Novel Therapies and Approaches for Management of Gynecologic Cancers

**Session Type:** Clinical Science Symposium

**Date:** Monday, June 7

**Location:** E Arie Crown Theater

**Time:** 9:45 AM - 11:15 AM

- Novel Therapies and Approaches for Management of Gynecologic Cancers  
*Robert L. Coleman, MD*
- Novel Therapies and Approaches for Management of Gynecologic Cancers  
*Ronald J. Buckanovich, MD*
- #5000-Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.  
*Beth Y. Karlan*
- Discussion: Anti-angiogenic options in Ovarian Cancer. (Please take note of other PK abstract with AMG 386.Abst 47850)  
*George Coukos, MD, PhD*
- #5001-Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.

- #5002-Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.

*Hal W. Hirte*

- Discussion: Mechanisms of resistance in ovarian cancer.

*Hani Gabra, PhD, FRCP*

---

**Session Title:** #226: Promising Targeted Therapies for Head and Neck Cancer

**Session Type:** Clinical Science Symposium

**Date:** Monday, June 7

**Location:** E354a

**Time:** 9:45 AM - 11:15 AM

- Promising Targeted Therapies for Head and Neck Cancer

*Bonnie S. Glisson, MD*

- #5500-Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02.

*Sandra Schmitz, MD*

- Discussion

*Bonnie S. Glisson, MD*

- #5501-BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

*Tanguy Y. Seiwert, MD*

- #5502-Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.

*Razelle Kurzrock, MD*

- Discussion

*Manisha H. Shah, MD*

---

**Session Title:** #266: American Cancer Society Award and Lecture

**Session Type:** Special Session

**Date:** Monday, June 7

**Location:** S100b

**Time:** 9:45 AM - 11:00 AM

- American Cancer Society Award and Lecture

*Joseph V. Simone, MD*

---

**Session Title:** #255: Melanoma/Skin Cancers

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** S406 (Vista Room)

**Time:** 11:00 AM - 12:00 PM

- Melanoma/Skin Cancers

*Ravi K. Amaravadi, MD*

- Melanoma/Skin Cancers

*Gregory A. Daniels, MD, PhD*

1 #8513-Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008.

*Jeffrey Alan Sosman, MD*

2 #8514-Early ultrasound criteria drive sensitivity for detection of sentinel node metastases in melanoma patients: A prospective study in 800 patients.

*Christiane A. Voit*

3 #8515-Report card for compliance with NCCN guidelines in the surgical management of cutaneous melanoma across the United States: Time for remedial classes?

*Nabil Wasif*

4 #8516-Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study.

*Michael B. Atkins, MD*

5 #8517-Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008.

*Vernon K Sondak, MD*

- Discussion

*Julie R. Lange, MD*

6 #8518-Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers.

*Lore Decoster, MD*

7 #8519^--A phase II randomized study of ramucirumab (IMC□1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).

*Richard D. Carvajal*

8 #8520-Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic melanoma.

*Valerie P Grignol, MD*

9 #8521-First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).

*Reinhard Dummer*

10 #8522-Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma.

*Roger Mouawad*

- Discussion

*David F. McDermott, MD*

11 #8523-Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

*Donald P. Lawrence*

12 #8524-Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.

*Ahmad A. Tarhini*

13 #8525-Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma.

*Omid Hamid*

14 #8526-Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.

*Axel Hauschild*

- Discussion

*Henry B. Koon, MD*

15 #8527-A phase II study of imatinib for advanced melanoma patients with KIT aberrations.

*Jun Guo, MD, PhD*

16 #8528-Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).

*Lynn G. Feun*

17 #8529-Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.

*Grant A. McArthur, PhD*

18 #8530-Phase II study of vorinostat in patients with advanced melanoma.

*Naomi B. Haas*

19 #8531-Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.

*Wen-Jen Hwu*

20 #8532-A phase I/II trial of DTIC and dasatinib in metastatic melanoma.

*Alain Patrick Algazi*

- Discussion

*Anna C. Pavlick, MD*

---

**Session Title:** #7: Addressing the Cost of Cancer Care with Patients: Practice-based Strategies for Communicating the "New Bad News"

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E353

**Time:** 11:30 AM - 12:45 PM

- Communication about Cost of Cancer Care

*Lidia Schapira, MD*

- Communicating the Costs and Benefits of Medical Interventions

*Deborah Schrag, MD*

- Inside the Patient-Physician Encounter: Communication and Value

*Anthony Back, MD*

---

**Session Title:** #14: Are We Asking Too Much? The Challenges of Mandatory Research Biopsies within Clinical Trials

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100b

**Time:** 11:30 AM - 12:45 PM

- WHAT CAN WE LEARN?: The scientific justification for consideration of mandatory research biopsy within some clinical trials. What questions can research biopsies address? Are they safe? What have we learned from such studies? What is at stake if make all correlative science components optional?

*Eric P. Winer, MD*

- ARE WE ASKING TOO MUCH?: Ethical Concerns over Mandatory Research Biopsy: Concerns over coercion. Need to separate therapeutic trials from correlative studies. Perspectives of a Patient Advocate within a National Cancer Institute Cooperative Group.

*Michael Katz*

- THE ETHICAL FRAMEWORK: Can we pursue mandatory research biopsy under select circumstances? Ethical arguments for mandatory research biopsy, ways to promote protection of research subjects and pursue important research. A proposed framework for consideration of mandatory research biopsy and clarification of the assumptions underlying different positions on this issue.

*Jeffrey M. Peppercorn, MD, MPH*

---

**Session Title:** #47: Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Arie Crown Theater

**Time:** 11:30 AM - 12:45 PM

- Phase III trial results and the impact on standard of care and trial design

*Michael J. Morris, MD*

- Second line treatment after docetaxel

*Kim N. Chi, MD, FRCPC*

- Bone directed therapy for prostate cancer: present standards and potential new options

*Evan Y. Yu, MD*

---

**Session Title:** #123: The Hospital/Physician Relationship: Tensions Arising

**Session Type:** Special Session

**Date:** Monday, June 7

**Location:** E354a

**Time:** 11:30 AM - 12:45 PM

- Where We Have Been, Where We Are: The Life of a Practice and the Pros and Cons of Intersecting with the Hospital

*Barbara L. McAneny, MD*

- Options for Practice and for Hospitals: How to Balance For-profit and Nonprofit Entities?

*Michael L. Blau, JD*

- Why We Must Cooperate: An Integrated Health Care Delivery Model Is Important - Cost and Quality and Survival

*Lowell E. Schnipper, MD*

- The Future Drives Us Together: New Payment Schemes - Where Episode of Care Leaves Oncology? Can You Survive Outside of the Institution?

*Hoangmai Pham, MD, MPH*

---

**Session Title:** #133: Management of Less Common Head and Neck Cancers

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 11:30 AM - 12:45 PM

- Salivary gland cancer

*David J. Adelstein, MD*

- Nasopharyngeal carcinoma

*Quynh-thu Le, MD*

- Cutaneous melanoma of the head and neck

*Carol Rossier Bradford, MD*

---

**Session Title:** #247: Genitourinary (Prostate) Cancer

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 12:00 PM - 1:00 PM

- Genitourinary (Prostate) Cancer

*Andrea Lynne Harzstark, MD*

- Genitourinary (Prostate) Cancer

*Daniel W Lin*

1 #4544-A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis.

*Nicholas Mitsiades, MD, PhD*

2 #4545-Bone scan "flare" in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

*Shreya K. Shah*

3 #4546-Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.

*Aseem Anand*

4 #4547-Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC).

*Eleni Efstathiou*

5 #4548-Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity.

*Tomasz M. Beer, MD, FACP*

6 #4549-The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized trials.

*Emmanuel S. Antonarakis, MD*

- Discussion: Biomarkers of response in prostate cancer

*Johann Sebastian De Bono, MD, PhD*

7 #4550-Predictors of outcome and subgroup results from the integrated analysis of sipuleucel- $\tau$ ; trials in metastatic castration-resistant prostate cancer.

*Celestia S. Higano, MD*

8 #4551-Persistence of immunotherapy survival effects of sipuleucel- $\tau$ ; and relationship to postrandomization docetaxel use in phase III studies.

*Daniel Peter Petrylak*

9 #4552-Correlation between product parameters and overall survival in three trials of sipuleucel- $\tau$ ; , an autologous active cellular immunotherapy for the treatment of prostate cancer.

*Frances P Stewart*

- Discussion: Can we predict who will respond to immunotherapy?

*Robert Dreicer, MD*

10 #4553-Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).

*Paul L. De Souza*

11 #4554-Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts).

*Daniel Keizman*

12 #4555-Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy.

*Mark T. Fleming*

13 #4556-ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

*Mark N. Stein*

14 #4557-Association between genetic polymorphisms in *SLCO1B3* gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC).

*Mary-Ellen Taplin, MD*

- Discussion: Novel therapies and response predictors for CRPC

*Celestia S. Higano, MD*

15 #4558-Dynamics of bone mineral density during intermittent androgen deprivation for men with biochemical recurrence of prostate cancer.

*Evan Y. Yu, MD*

16 #4559-Fractures and post-fracture mortality in elderly prostate cancer (PC) patients receiving androgen deprivation therapy (ADT) in the United States.

*Karynsa Cetin*

17 #4560-The effect of ADT on objective cognitive performance and self-reported cognitive function in men with prostate cancer.

*Shireen Marzouk*

- Discussion: The impact of ADT on bone and brain

*Matthew Raymond Smith, MD, PhD*

18 #4561-The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

*David G Bostwick*

19 #4562-Effect of inflammation on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

*Otis W. Brawley*

20 #4563-Positive biopsy (bx) rates for prostate cancer (PCA) based on prostate specific antigen (PSA) grouping in a large cancer screening trial: Prostate, lung, colorectal, and ovarian cancer screening trial (PLCO).

*Douglas Reding*

21 #4564-Cancer genetics-guided discovery of serum biomarker signatures for prostate cancer.

*Silke Gillissen*

22 #4565-Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer.

*E. David Crawford*

- Discussion: Risk identification, chemoprevention, surveillance and neoadjuvant therapy in early prostate cancer

*Joel B. Nelson, MD*

---

**Session Title:** #253: Lung Cancer - Metastatic

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 12:00 PM - 1:00 PM

- Lung Cancer - Metastatic

*Taofeek Kunle Owonikoko, MD*

- Lung Cancer - Metastatic

*Shirish M. Gadgeel, MD*

1 #7512-Use of ERCC1 expression levels in circulating tumor cells to predict response to platinum-based chemotherapy in patients with non-small cell lung cancer.

*Andreas Claudius Hoffmann*

2 #7513-Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy.

*David R. Gandara*

3 #7514-Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies.

*Rafael Rosell*

5 #7516-Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.

*Bruce E. Johnson, MD*

6 #7517-Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).

*Lecia Sequist, MD*

- Discussion: Biomarkers

*Michael J. Kelley, MD*

7 #7518-A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03).

*Rabab Mohamed Gaafar*

8 #7519-Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

*Lampros Vamvakas*

9 #7520-Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI).

*Geoffrey Raymond Oxnard*

10 #7521^~A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2).

*Chih-Hsin Yang*

11 #7522-Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504).

*Suresh S. Ramalingam, MD*

12 #LBA7523-Efficacy and safety of PF299804 versus (v) erlotinib (E): a global, randomized phase (P) 2 trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).

*Michael J. Boyer*

13 #7524-Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).

*Natasha B. Leigh*

- Discussion: New approaches in EGFR targeted therapy

*Karen L. Reckamp, MD, MS*

14 #7525-Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR).

*Jin Soo Lee*

15 #7526-Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

*Fairooz F. Kabbinavar*

16 #7527-A multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical effects of paclitaxel-carboplatin (TC) alone or with endostatin for advanced non-small cell lung cancer (NSCLC).

*Baohui Han*

17 #7528-Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

*George R Blumenschein, Jr, MD*

- Discussion: Anti-angiogenic agents

*Silvia Novello, MD, PhD*

19 #7530-Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605).

*Hiroshige Yoshioka*

20 #7531-Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

*Thomas James Lynch*

22 #7533-Randomized trial of concurrent versus sequential docetaxel (Doc) plus bortezomib (PS-341) in platinum pretreated non-small cell lung cancer (NSCLC).

*Primo Lara, MD*

23 #7534-A randomized phase II study of paclitaxel (P) and carboplatin (C) &plusmn; bevacizumab (B) &plusmn; dulanermin (D) in non-small cell lung cancer (NSCLC).

*Fiona Hellen Blackhall*

24 #7535-Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).

*Christos Stelios Karapetis*

- Discussion: New agents

*Suresh S. Ramalingam, MD*

**Session Title:** #166: Sarcoma

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** S406 (Vista Room)

**Time:** 1:00 PM - 4:00 PM

- Sarcoma

*Mark Agulnik, MD*

- Sarcoma

*Richard Riedel, MD*

- #10000-Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

*Alberto S. Pappo, MD*

- #10001-AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results.

*William D. Tap, MD*

- #10002-Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors.

*Richard Hong Hui Quek*

- Discussion

*Jeffrey Toretsky, MD*

- #10003-Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS).

*Alessandro Gronchi*

- #10004-A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).

*Claire F. Verschraegen, MD*

- #10005-Identification of selective inhibitors of dedifferentiated liposarcoma cells by high-throughput screening (HTS).

*Christina Vadala Angeles, MD*

- Discussion

*Andrew J. Wagner, MD, PhD*

- #10006-Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.

*Christopher Corless*

- #10007-In vitro activity of novel KIT/PDGFRα switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors.

*Michael C. Heinrich, MD*

- #10008-Succinate dehydrogenase in *KIT/PDGFRα* wild-type gastrointestinal stromal tumors.

*Katherine A. Janeway*

- Discussion

*Robert D Marsh, MD*

---

**Session Title:** #201: Genitourinary Cancer

**Session Type:** General Poster Session

**Date:** Monday, June 7

**Location:** S Hall A2

**Time:** 1:00 PM - 5:00 PM

1A #4566-The impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The M. D. Anderson Cancer Center experience.

*Siobhan P Lynch*

1B #4567-Impact of dose density of adjuvant chemotherapy for locally advanced urothelial cancer.

*Tanya B. Dorff*

1C #4568-Concentration-depth profiles of mitomycin-C in the human bladder wall after passive diffusion, thermochemotherapy, and electromotive drug administration.

*Gioia Leprini*

1D #4569-Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028.

*Derek Raghavan, MD, PhD*

1E #4570-The impact of a bladder cancer diagnosis on smoking behavior: An opportunity to improve care.

*Jeffrey C Bassett*

1F #4571-Evaluation of African American ethnicity and socioeconomic status as prognostic factors for overall survival in bladder cancer.

*Fen Jiang*

1G #4572-Gene expression profile of advanced squamous and transitional cell carcinoma of the bladder.

*Hussein Mustafa Khaled*

1H #4573-Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC).

*Matt D. Galsky*

2A #4574-Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05).

*Susanne Krege*

2B #4575-Validation of a trimodality treatment and selective organ preservation for bladder cancer: Influence of clinical different parameters on the 15-year long-term outcome.

*Frens Steffen Krause*

2C #4576-Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy.

*Guru Sonpavde*

2D #4577-Comparison of HER2 amplification in primary tumors and lymph node metastases of urinary bladder cancer.

*Achim Fleischmann*

2E #4578-Influence of age and socioeconomic status (SES) on testicular cancer (TC) specific mortality: A population-based study of 27,948 patients.

*Sophie D. Fossa, MD*

2F #4579-Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy.

*Andreas Burchert*

2G #4580-Management of testicular neoplasms in France and compliance with national guidelines.

*Stephane Culine*

2H #4581-2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: A retrospective validation of the SEMPET trial.

*Mark Bachner*

3A #4582-Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell cancer: A CUOG/GTCSG cooperative phase II study.

*Christian K. Kollmannsberger, MD*

3B #4583-Progression-free survival (PFS) as a new endpoint for designing phase II trials in patients with refractory germ cell tumors (GCT).

*Darren Richard Feldman*

3C #4584-Impact of delayed orchiectomy (OE) on overall survival (OS) in patients (pts) with metastatic germ cell tumors (mGCT).

*Mikhail Fedyanin*

3D #4585-Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin +/- paclitaxel.

*Karin Oechsle*

3E #4586-Residual tumor resection in patients with germ cell tumors (GCT): Use of IGCCCG risk group and tumor volume to predict additional vascular procedures.

*Christian Winter*

3F #4587-Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy (CT) in nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis: A phase II study.

*Alexey Tryakin*

3G #4588-A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib.

*Asim Amin*

3H #4589-Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC).

*Giuseppe Procopio*

4A #4590-A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC).

*Jonathan E. Rosenberg, MD*

4B #4591-Interleukin-2 (IL-2) based immunotherapy for the treatment of metastatic renal cell carcinoma (mRCC): An analysis of 422 consecutive patients treated between 1999 and 2008.

*Frede Donskov*

4C #4592-Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma (mRCC) receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone.

*Pierre Karakiewicz*

4D #4593-Use of the UCLA-integrated staging system (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma.

*Frederic Pouliot*

4E #4594-TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN- $\alpha$ );).

*Sujata Patil*

4F #4595-Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial.

*Pasi Korhonen*

4G #4596-Patient preferences for targeted agents in renal cell carcinoma (RCC): A benefit&ndash;risk conjoint study.

*A. Brett Hauber*

4H #4597-Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa (IFN- $\alpha$ );): Analysis of the pivotal randomized trial.

*Julia Wilkerson*

5A #4598-Epidemiological trends in renal cell carcinoma (RCC) in the cytokine (CYT) and targeted therapy (TT) eras: A registry analysis of 28,252 patients (pts).

*Derek Way-Jun Shek*

5B #4599-Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

*Pankaj Bhargava*

5C #4600-Complete remission with TKI in renal cell carcinomas: Experience in 65 patients of the French Kidney Cancer Group.

*Laurence Albiges*

5D #4601-A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib.

*Nasreen A. Ilias-Khan*

5E #4602-Risk of congestive heart failure with VEGF-targeted therapy: A systematic review and meta-analysis of clinical trials.

*Fabio Augusto Barros Schutz*

5F #4603-The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

*Thomas Powles*

5G #4604-Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study.

*Elizabeth Rosenberg Plimack*

5H #4605-Sorafenib (SOR) safety profile in more than 4,600 patients (pts) with renal cell carcinoma (RCC): Assessment at 3-month (mo) intervals using an integrated database of eight company-sponsored studies.

*Martin Gore*

6A #4606-Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma.

*Zita Dubauskas Lim*

6B #4607-Presurgical bevacizumab and sunitinib induced changes in primary clear cell renal tumor tissue.

*Axel Bex*

6C #4608-Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).

*Susanne Osanto, MD, PhD*

6D #4609-Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients.

*Georges R Azzi*

6E #4610-Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC).

*Ana M. Molina*

6F #4611-An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients.

*Roman Casciano*

6G #4612-Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.

*Gerald Hans Mickisch*

6H #4613-Outcome of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN).

*Stephen Lane Richey*

7A #4614-Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos).

*Thomas E. Hutson*

7B #4615-Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating t-regulatory cells (TREG).

*Rodolfo Passalacqua*

7C #4616-Risk of primary progressive disease with tyrosine kinase inhibitors sorafenib and sunitinib in patients with renal cell carcinoma: A meta-analysis

*Xiao Su*

7D #4617-Effect of GSK-3 inhibition in vitro and in vivo on antitumor effect of sorafenib in renal cell carcinoma (RCC).

*Hisashi Kawazoe*

7E #4618-Detection of circulating tumor cells in patients with renal cell carcinoma compared with a control group.

*Thomas Gutsch*

7F #4619-Correlation of regulatory T-cell levels and overall survival in metastatic renal cancer patients treated with sunitinib-based therapy.

*Eric Tartour*

7G #4620-The effect of sunitinib on immune parameters and haemopoetic stem cell markers in patients with untreated clear cell renal cancer.

*Simon Chowdhury*

7H #4621-Fibroblast growth factor pathway in renal cell carcinoma.

*Ilya Tsimafeyev*

8A #4622-Expression of enhancer of zeste homolog 2 in renal cell carcinoma and relationship to downregulation of micro RNA-101.

*Toshihiko Sakurai*

8B #4623-Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice.

*Nicole Marie Agostino*

8C #4624-Renal cell carcinoma in octogenarians: Comprehensive analysis using the SEER database.

*Nicholas J Hellenthal*

8D #4625-Single-fraction radiosurgery for treatment of spinal and cerebral metastases from renal cell carcinoma under systemic tyrosine kinase inhibition.

*Michael D. Staehler*

8E #4626-Metastatic renal cell carcinoma (mRCC): Relationship between initial non-renal RECIST-target metastases hypoxia, change after 1 month of sunitinib and therapeutic response: An 18f-MISO PET-CT study.

8F #4627-Pro-BNP for detection of sunitinib-induced cardiac toxicity in patients with renal cell carcinoma.

*Manuela Schmidinger*

8G #4628-Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor (b-FGF) as predictive factors for sorafenib plus interferon-alfa-2a (IFN) in metastatic renal cell carcinoma (MRCC): Biologic results from the randomized phase II RAPSODY trial.

*Sergio Bracarda*

8H #4629-Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib.

*Jenny J. Kim*

9A #4630-Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC).

*Andrea J. Bullock*

9B #4631-Serum lactate dehydrogenase (LDH) is a predictive biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).

*Andrew J. Armstrong, MD, ScM*

9C #4632-A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902.

*Howard Mark Sandler*

9D #4633-Treatment of intermediate- or high-risk prostate cancer by dose escalation with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B): Early results of a prospective comparative trial.

*Benjamin Guix*

9E #4634-Phase I/II trial of combined hormonal therapy and hypofractionated accelerated radiotherapy with concomitant intensity-modulated boost for high-risk prostate cancer: Toxicity analysis.

*Harvey Quon*

9F #4635-Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy.

*Daniel Costin Danila*

9G #4636-A sensitive exosome-based biosignature for the diagnosis of prostate cancer.

*Christine Kuslich*

9H #4637-Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial.

*Gregory Russell Pond*

10A #4638-Fluorodeoxyglucose (FDG) PET as an outcome measure for metastatic prostate cancer.

*Michael J. Morris, MD*

10B #4639-Association of genetic polymorphisms in ERCC1 gene with PSA response to carboplatin chemotherapy in men with metastatic castration-resistant prostate cancer (CRPC).

*Mari Nakabayashi, MD, PhD*

10C #4640-Serum-free circulating DNA as a biomarker of prostate cancer diagnosis.

*Edna Gordian*

10D #4641-Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen deprivation (IAD).

*Victoria J. Sinibaldi*

10F #4643-Effect of tissue ischemia on prostatic androgen levels.

*Michael Christopher Risk*

10G #4644-Prognostic value of metastasis pattern for morbidity in prostate cancer measured by quantitative bone scintigraphy.

*Martin Hoejgaard, MD*

10H #4645-Performance of expressed prostatic secretion assays in prediction of surgical pathology outcomes in patients undergoing radical prostatectomy.

*Chris M Whelan*

11A #4646-Correlation of epigenetic silencing of *SOCS3* with a subset of prostate cancer with aggressive behavior.

*Francesco Pierconti*

11B #4647-Prostate cancer metastasis, the non-canonical Wnt pathway and the transcription factor PITX2.

*Ian Vela*

11F #4648-PCA3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy.

*Koji Okihara*

11G #4649-Neuroendocrine carcinoma in conjunction with Gleason score 8-10 prostate cancer: Clinical implications for patients treated with radiotherapy.

*Daniel J Krauss*

11H #4650-Molecular markers that predict for recurrence in men with margin-positive localized prostate cancer.

*Po Yee Yip*

12A #4651-Use of a pretreatment systems pathology model to predict the likelihood of disease progression in patients treated with primary radiotherapy.

*Michael J. Donovan*

12B #4652-Expression of EGFR and HER2/neu and absence of activating mutations in patients with castration-resistant prostate cancer.

*Carsten Henning Ohlmann*

12F #4653-Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial.

*Matthew Raymond Smith, MD, PhD*

12G #4654-Prostate cancer in men under the age of 50: A comparison of race and outcomes.

*Patrick M Parker*

12H #4655-Who receives chemotherapy: An analysis of stage IV prostate cancer (PCa) patients in SEER-Medicare.

*Michael Grabner*

13A #4656-A population based study of cardiovascular (CV) mortality among patients with prostate cancer (PCa) treated with radical external beam radiation therapy (EBRT) with and without adjuvant androgen deprivation therapy (ADT) at a provincial cancer agency.

*Julian Oliver Kim*

13B #4657-A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned.

*James L. Gulley, MD, PhD, FACP*

13C #4658-Patterns of use of docetaxel in stage IV prostate cancer (PCa) patients in SEER-Medicare.

*Eberechukwu Onukwugha*

13D #4659-Characteristics of men with abnormal prostate-specific antigen (PSA) who had a biopsy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

*William Gray Hocking, MD*

13E #4660-Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostate cancer (CPRC).

*Geoffrey Colin Buckle*

13F #4661-A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer patients with associated cytokine changes.

*Geoffrey Gibney*

13G #4662-A phase II study of pre-operative figitumumab (F) in patients (pts) with localized prostate cancer (PCa).

*Kim N. Chi, MD, FRCPC*

13H #4663-Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel.

*Vassiliki Tzelepi*

14A #4664-Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety.

*Donald L. Trump*

14B #4665-Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC).

*Farshid Dayyani*

14C #4666-Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07).

*Richard Cathomas*

14D #4667-Phase I trial of fractionated-dose <sup>177</sup>lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (<sup>177</sup>Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).

*Scott T. Tagawa*

14E #4668-Phase II trial of lapatinib in patients in stage D0 prostate cancer (E5803): Effect of Kras and EGFR status on clinical outcome.

*Yu-Hui Chen*

14F #4669-Phase I, dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC).

*Michael Anthony Carducci*

14G #4670-The effect of inhibition of the insulin-like growth factor receptor with nordihydroguaiaretic acid on PSA progression: Results of a phase II study.

*Terence W. Friedlander*

14H #4671-Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred).

*Charles J. Ryan*

15A #4672-Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC).

*Diletta Bianchini*

15B #4673-Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.

*Neal D. Shore*

15C #4674-HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial.

*Robert B. Montgomery*

15D #4675-Association of ADT for older men with biochemical recurrence of prostate cancer with obese frailty and falls: A case-control study.

*William Dale, MD, PhD*

15E #4676-Effect of toremifene on fracture risk in men younger than age 80 on androgen-deprivation therapy.

*Michael K Brawer*

15F #4677-Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) +/- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747.

*Emilio Porfiri*

15G #4678-Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials.

*Sten Nilsson*

15H #4679-Analysis of the cost-effectiveness of zoledronic acid for the prevention of skeletal related events in patients with prostate cancer and bone metastases: A comparison across four European countries.

*Marc Botteman*

16A #4680-Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride (alpharadin) in patients with castration resistant prostate cancer (CRPC) metastatic to bone.

*Jorge A. Carrasquillo*

16B #4681-Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer patients (GETUG-AFU 15/0403).

*Igor Latorzeff*

16C #4682-Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC).

*Christoph W Reuter*

16D #4683-Phase II trial of non pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: A translational study.

*Marco Montanari*

16E #4684-Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.

*Eric Jay Small, MD*

16F #4685-Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy +/- docetaxel: An analysis of final safety results.

*Stéphane Oudard*

16G #4686-Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study.

*Saroj Niraula*

16H #4687-Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer.

*Dale Randall Shepard*

17A #4688-A phase I study of combined docetaxel and repeated high activity rhenium-186- HEDP in castration resistant prostate cancer metastatic to bone (the TAXIUM trial).

*Joyce M van Dodewaard-de Jong*

17B #4689-Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC).

*Andrea Lynne Harzstark, MD*

17C #4690-Correcting overall survival (OS) effect for the impact of cross-over via rank preserving structural failure time (RPSFT) model: Case of mRCC RECORD-1 trial of everolimus (EVE).

*Emmanuel Zuber*

**Session Title:** #204: Health Services Research

**Session Type:** General Poster Session

**Date:** Monday, June 7

**Location:** S Hall A2

**Time:** 1:00 PM - 5:00 PM

18A #6034-Effect of computerized physician order entry (CPOE) on chemotherapy prescribing error.

*Rob Stein, MB,ChB,PhD,FRCP*

18B #6035-RCT of community-based patient assistance to improve breast cancer care.

*Nina Bickell*

18C #6036-Evaluating psychosocial and belief differences in a diverse racial and socioeconomic cancer population.

*Blase N. Polite*

18D #6037-Cost-effectiveness of lapatinib plus capecitabine (LAP+C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ+C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the U.K. National Health Service (NHS) perspective.

*Oleg Sofrygin*

18E #6038-Impact of medicaid-enrollment status/timing on stage at diagnosis among male cancer patients.

*Katherine S. Virgo, PhD, MBA*

18F #6039-Use of a 21-gene reverse transcriptase-polymerase chain reaction (RT-PCR) assay to guide therapy in 14 Michigan Breast Oncology Quality Initiative (MiBOQI) sites.

*Samuel M. Silver, MD, PhD, FACP*

18G #6040-Barriers to treatment in patients with locally advanced breast cancer.

*Laura Bourdeanu*

18H #6041-Physician's perspectives and racial disparity in the surgical treatment of early lung cancer.

*Paul R. Walker*

19A #6042-Cost-effectiveness of adding information about common risk alleles to current decision models for breast cancer chemoprevention.

*Tuan Dinh*

19B #6043-Initial use of newer agents for advanced non-small cell lung cancer: Evidence from the National Cancer Institute patterns of care study.

19C #6044-Analysis of the cause of discordance between two radiologists on the assessment of radiographic response and progression for subjects enrolled in breast cancer clinical trials employing blinded independent central review.

*Kristin Borradaile, MS*

19D #6045-Communication of the essential elements of informed consent (IC) for research: A RIAS analysis of phase I clinical trial encounters.

*Christopher Daugherty, MD*

19E #6046-The impact of routine pathology review on treatment for node-negative breast cancer.

*Hagen F. Kennecke*

19F #6047-Characterization of prostate cancer treatment information quality obtained through Yahoo, Google, and Bing search engines.

*Danny Landau, MD*

19G #6048-Costs of absenteeism and short-term disability associated with breast cancer to U.S. employers.

*Sean D Sullivan*

19H #6049-Changes in chemotherapy uptake and wait times in early-stage non-small cell lung cancer (NSCLC).

*Samantha Lee Gray*

20A #6050-Global variations in reimbursement of new cancer therapeutics: Improving access through risk-sharing agreements.

*Parneet Kaur Cheema*

20B #6051-Medical oncologists and quality of life of women treated for breast cancer.

*Christopher Ryan Friese*

20C #6052-Equipoise lost: Ethics, costs, and the regulation of cancer clinical research.

*David J Stewart*

20D #6053-Practice standardization in the staging and treatment of colon cancer at Intermountain Healthcare.

*Jonathan R. Whisenant*

20E #6054-Impact of cancer on the quality of life and health status of patients and their family members.

*Ya-Chen T. Shih*

20F #6055-Health care cost of breast cancer: A claims data analysis.

*Alex Z Fu*

20G #6056-Comparison of the Veterans Affairs Oncology Registry and the SEER Cancer Registry among patients with lung cancer.

*Steven B. Zeliadt*

20H #6057-Unmet psychosocial needs among cancer patients at the national cancer centre Singapore (NCCS).

*Raymond C.H. Ng*

21A #6058-Accuracy of cancer information on the Internet: A comparison of a Wiki with a professionally maintained database.

*Malolan S Rajagopalan, BS*

21B #6059-Quality of published studies supporting off-label and accelerated approval oncology indications.

*Kenneth Robert Carson*

21C #6060-Effects of ethnicity on genotype-phenotype correlations in individuals with a *BRCA1* or *BRCA2* mutation.

*Michelle Jackson, MS, CGC*

21D #6061-The impact of breast care nurses on early-stage breast cancer patients' perception of quality of care: The results of a multilevel regression analysis.

*Christoph Kowalski*

21E #6062-Consenting factors in clinical cancer research: Observations from a cancer center tissue repository.

*David E. Gerber*

21F #6063-Changing rates of organ-preservation therapy over time for head and neck cancer: A SEER-Medicare analysis.

*David J Sher*

21G #6064-Social, biological, and tumor characteristics of 139 African American (AA) women with newly diagnosed breast cancer in Chicago.

*Sarah J. Gehlert*

21H #6065-FDA accelerated approval of anticancer agents.

*Yangmin M. Ning*

22A #6066-Protocol performance metrics and resource utilization of phase II investigator-initiated trials.

*Henry Durivage*

22B #6067-Factors influencing use of genetic tests in clinical practice among U.S. oncologists.

*Jeffrey M. Peppercorn, MD, MPH*

22C #6068-Treatment delays in non-small cell lung cancer (NSCLC) and their prognostic implications.

*Razvan Diaconescu, MD*

22D #6069-Nature and outcome of clinical trials conducted by the Eastern Cooperative Group (ECOG) from 1977 to 2006.

*Ronald S. Go*

22E #6070-Factors contributing to delays in breast cancer management.

*Erica Barlow*

22F #6071-Impact of Medicare's July 2007 erythropoiesis-stimulating agent (ESA) national coverage determination (NCD) on transfusion use in chemotherapy-treated cancer patients.

*Tom Arneson*

22G #6072-Influence of patient beliefs and patient knowledge on adherence to hormone treatment for breast cancer.

*Kathie-Ann P. Joseph*

22H #6073-Understanding premature discontinuation of aromatase inhibitor (AI) therapy in postmenopausal breast cancer survivors.

*Carrie Tompkins Stricker*

23A #6074-Predictors of BRCA-positive parents' disclosure of cancer risk and risk reduction options to offspring.

*Linda J. Patrick-Miller*

23B #6075-The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel.

*Shmuel Klang*

23C #6076-Follow-up of abnormal pap smear results: A population-based study.

*Rachel Kupets*

23D #6077-NCI Cancer Trials Support Unit at year 10.

*Stephen E Riordan*

23E #6078-Retrospective health care claims database analysis of direct medical costs of newly diagnosed patients (pts) with hepatocellular carcinoma (HCC) in the United States.

*Andrew Stewart Poklepovic*

23F #6079-Using administrative data to describe adherence to colon cancer follow-up testing in Manitoba, Canada.

*Jeffrey J Sisler*

23G #6080-Information technology (IT) and chemotherapy (CT) prescribing errors.

*Marianna Aita*

23H #6081-Strategies to increase access to quality genetic testing services: Case study of *BRCA1/2* testing.

*Benjamin Kim*

24A #6082-Synergy made simple: What does it mean and how valid are claims for synergy between antitumor agents?

*Alberto Ocana*

24B #6083-Treatment patterns by oncologists and urologists for castration-resistant prostate cancer (CRPC).

*Berhanu Alemayehu, DrPH*

24C #6084-Analysis of cancer clinical trials in the United States with comparison of National Institute of Health (NIH) and pharmaceutical industry (PHARMA)-sponsored studies.

*Kurt R. Oettel*

24D #6085-Rural-urban disparity in cancer screening among elder Medicare beneficiaries: Does rurality matter?

*Lin Fan*

24E #6086-Small world networks and treatment discovery process in cancer.

*Athanasios Tsalatsanis*

24F #6087-Baseline MUGA scans for patients with early-stage breast cancer receiving adjuvant chemotherapy.

*Alwin S. Jeyakumar*

24G #6088-Neutropenic risk, use of colony-stimulating factors, and impact on the relative dose intensity of administered chemotherapy.

*William Baxter Webb*

24H #6089-A prospective evaluation of the patients' knowledge about their chemotherapy treatment (CT) before the first course.

*Nelson Kohen*

25A #6090-Dose reductions and delays in patients (pts) with renal cell carcinoma (RCC) treated with sorafenib (SR) or sunitinib (SU): Retrospective analysis of two large U.S. health care claims databases.

*Stephen Michael Keefe*

25B #6091-Pattern of aromatase inhibitor use in males.

*Milayna Subar*

25F #6092-Concomitant medication (CM) use in phase I and II cancer clinical trials (CCT): Effects on trial eligibility and potential interactions with study medications.

*Martin Benjamin*

25G #6093-Evaluation of multidisciplinary (MultiD) care in thoracic oncology.

*Gregory L Phelps*

25H #6094-The role of NCI-sponsored research in ASCO clinical cancer advances 2005-2008.

*Brian Zuckerman, PhD*

26A #6095-Adherence to cardiovascular (CV) medications after myocardial infarction (MI) in cancer survivors (CS).

*Soko Setoguchi*

26B #6096-Quality and consistency in breast cancer clinical guidelines internationally: Are we globally consistent?

*Christine E. Simmons*

26F #6097-The relationship between service quality measures and patient willingness to recommend at a national oncology provider network: The Cancer Treatment Centers of America experience.

*Digant G Gupta*

26G #6098-Patients' views on delayed diagnosis in cancer.

*Thomas H. Gallagher*

26H #6099-Optimal chemotherapy utilization rate in cancer care: Setting an evidence-based benchmark for quality improvement.

*Weng Leong Ng*

27A #6100-Patients' willingness to be informed on cancer clinical trials.

*Iris Pauporte*

27B #6101-Utility of routine cardiac ejection fraction (EF) measurement prior to anthracycline-based chemotherapy (ABC) in patients with diffuse large b-cell lymphoma (DLBCL).

*Amber L Conrad, MS, PA-C*

27C #6102-Treatment strategies for low-risk febrile neutropenia in adult cancer patients: A cost-utility analysis.

*Oliver Teuffel*

27D #6103-What are physician and patient factors important for proper follow-up of high-grade Pap smear abnormalities?

*Lawrence Frank Paszat*

27E #6104-The shortage of medical oncologists and low chemotherapy utilization in Australia.

*Bogda Koczwara*

27F #6105-Nomogram to predict risk of 30-day mortality for patients with disseminated malignancy undergoing surgical intervention.

*Warren H Tseng*

27G #6106-Combination versus sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network.

*Marcus A. Neubauer*

27H #6107-Association of black race and outcomes in patients with nonmetastatic triple-negative breast cancer (TNBC): Results from a U.S. local oncology practice.

*Bruce A. Feinberg*

28A #6108-Calibration of quality-adjusted life years (QALYs) for oncology clinical trials (OCT).

*Jeff A. Sloan*

28B #6109-Relationship between neuroendocrine tumor-related symptoms and PROMIS health-related quality-of-life scores.

*Jennifer L Beaumont*

28C #6110-The value of concurrent symptoms in predicting clinical outcomes in lung cancer survivors.

*Andrea L. Cheville*

28D #6111-Prospective change in 25-OH vitamin D levels over long-term follow-up and health outcomes in breast cancer survivors.

*Sara Kristina Taylor, MD, CM*

28E #6112-Estimating minimally important differences (MID) for the worst pain rating of the brief pain inventory (BPI)-short form (SF).

*Susan D. Mathias*

28F #6113-The long-term impact of surgical complications after resection of stage I non-small cell lung cancer: A population-based survival analysis.

*Natasha M Rueth*

28G #6114-Cancer recurrence and survival in patients with early-stage triple-negative breast cancer in a U.S. local oncology practice.

*Lirong Zhao*

28H #6115-Evaluation of the state of health of patients with localized prostate cancer (cT1-cT2) compared to the normal population.

*Michael J. Mathers, MD, PhD*

29A #6116-Publication bias in randomized controlled trials (RCTs) of colorectal cancer presented at ASCO Annual Meetings.

*Alessandro I. C. Leal, MD*

29B #6117-The role of acculturation in end-of-life outcomes for Latino advanced cancer patients.

*Elizabeth Trice Loggers, MD, PhD*

29C #6118-Neuroendocrine tumor disease state and PROMIS health-related quality of life scores.

*David Cella*

30A #6119-Racial disparities in stage II prostate cancer outcomes in the Veterans Affairs hospital system.

*David Crockett*

30B #6120-A prospective paired survey of oncologist and patient attitudes toward therapeutic cancer clinical trial (CT) enrollment in a diverse academic health center patient population.

*Mandira Ray*

30C #6121-Impact of response shift in longitudinal postoperative quality of life (QoL) analysis among breast cancer (BC) patients: A randomized multicenter cohort study.

*Franck Bonnetain*

31A #6122-Adequacy of data provision and analysis in oncology phase III trials over the past 5 years.

*Hui Kong Gan*

31B #6123-The National Lung Cancer Audit in the United Kingdom: Results after four years.

*Paul Beckett*

31C #6124-Education level as prognostic factor of patients (pts) with advanced non-small-cell lung cancer (NSCLC) enrolled in clinical trials.

*Massimo Di Maio*

32A #6125-Relationship between survival and lymph node assessment from a population-based study of colorectal cancer patients.

*Robin Urquhart*

32B #6126-Comparison between the causes of rejection to participate (RP) and screening failures (SF) in oncology clinical trials (OCT).

*Luis A Fein*

32C #6127-Outcomes from placebo/best supportive care-controlled trials (PBSCT) in the era of molecular targeted therapy: A meta-analysis.

*Michele C. Miranda*

33A #6128-Is the informed consent (IC) to treatment truly "informed"? The use of a comprehension check tool (CCT).

*Rosalbino Biamonte*

33B #6129-Assuring continuous quality improvement using outcomes data: A potential role for cancer registries.

*Robert Owen Dillman*

33C #6130-Evaluation of hormone receptor and benefit from adjuvant chemotherapy in breast cancer patients with intermediate- and high-risk disease.

*Christian Kurzeder*

34A #6131-Second-line pancreatic cancer therapy: Patterns of care and survival.

*Susan Nga Hoang*

34B #6132-Effect of race and comorbidities on patterns of bevacizumab toxicity: A single-institution experience.

*Muhammad Raza*

34C #6133-Symptom burden in chronic myeloid leukemia (CML).

*Loretta A. Williams*

35A #6134-Correlation of 5-year survival and cure in NSCLC: An analysis of delayed cancer deaths in long-term survivors of NSCLC.

*Matthew O. Hubbard*

35B #6135-Impact of neoadjuvant chemotherapy on breast reconstruction.

*Yue-Yung Hu*

35C #6136-Can patient-reported kidney cancer&ndash;specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma?

*Peter C Trask*

35D #6137-Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting.

*J. Russell Hoverman*

35E #6138-Capturing breast cancer patients' experience beyond disease progression: Implementation of a patient-reported outcome (PRO) substudy in the VIRGO Metastatic Breast Cancer Observational Cohort study.

*Peter Andrew Kaufman*

35F #6139-Retrospective application of Nottingham Prognostic Index (NPI) and Adjuvant! Online tool in newly diagnosed patients with early breast cancer in mid-western Ireland.

*Keith Ian Quintyne*

35G #6140-Cost and outcome of vascular resections during pancreaticoduodenectomy.

*Griffin Bullock*

35H #6141-Technologic advancements and error rates in radiation therapy (RT) delivery.

*Danielle Nina Margalit, MD, MPH*

36A #6142-Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service.

*David A Hanauer*

36B #6143-Novel uses of coded data in clinical trials.

*Adam Daunton*

36C #6144-Factors influencing the career decisions of United States hematology oncology fellows training at NCI- and NCCN-designated cancer centers.

*Leora Horn*

36D #6145-Continuity of care for cancer patients at the end of life (EoL).

*Romeo Bascioni*

36E #6146-Care delivery barriers to personalized medicine in breast cancer.

*Julian C. Schink*

36F #6147-Hepatitis B screening prior to chemotherapy: A survey of practitioners' knowledge, beliefs, and screening practices.

*Ronita Lee*

36G #6148-The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB).

*Mira L Katz*

36H #6149-Prescribing and safety issues of oral molecular therapies and chemotherapies in Australian haematology oncology practice.

*Michael Joseph Dooley*

37A #6150-Comparison of hospital costs versus DRG reimbursement for treatment of febrile neutropenia during adjuvant CTX for primary breast cancer.

*Stefanie C Mayer*

37B #6151-Development and testing of multiple versions of a radiation oncology treatment planning workflow application in the era of HIPAA.

*John B. Fiveash*

37C #6152-Evaluating clinical trials: What exactly do medical oncologists know and use?

*Kenneth Robert Hoffman, MD, MPH*

37D #6153-Quantitative aspects of failure mode and effects analysis (FMEA) scoring in a prospective safety study of a large academic radiation oncology department.

*Stephanie Alicia Terezakis*

37E #6154-The 2008 National Comprehensive Cancer Network (NCCN) research benchmarking survey (RBS): Clinical trials (CTs) operations in the academic center.

*Stephen L Sherman*

37F #6155-Toxicity symptom reporting by patients and clinicians during phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer (GETUG-AFU 15/0403).

*Gwenaëlle Gravis*

37G #6156-ERCC, TS, RRM1, EGFR, and KRAS biomarker integration into a community-based medical oncology practice.

*Sandeep K. Reddy*

37H #6157-Fellowship characteristics associated with fellows' interest in pursuing clinical research: A National Comprehensive Cancer Network (NCCN) survey.

*Jennifer M Hinkel*

38A #6158-Physicians' nonverbal behaviors: Oncology patients perspective.

*Harris V. K. Naina*

---

**Session Title:** #210: Patient and Survivor Care

**Session Type:** General Poster Session

**Date:** Monday, June 7

**Location:** S Hall A2

**Time:** 1:00 PM - 5:00 PM

39A #9042-Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial.

*Saroj Vadhan-Raj*

39B #9043-Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): Results from a randomized phase III clinical trial.

*Roger von Moos*

39F #9044-Contraception after breast cancer: Results of a survey among French gynecologists.

*Hamid Hocini*

39G #9045-Treatment with antidepressant and anti-anxiety medications after breast cancer diagnosis in a large HMO.

*Virginia P. Quinn*

39H #9046-Development of a functional assessment of chronic illness therapy questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors: FACT-EGFRI.

*Lynne I. Wagner*

40A #9047-Fatigue after breast cancer adjuvant therapy influences health care utilization and perceived needs.

*Kate Webber*

40B #9048-Satisfaction with physician-patient discussions on fertility and sexual health among young women with cancer.

*Maura M Scanlon*

40F #9049-Utility of pre-chemotherapy echocardiographical assessment of cardiac abnormalities.

*Narayan Vaderahobali Karanth*

40G #9050-Evaluation of pandemic H1N1(2009) influenza vaccine in adults with solid tumor malignancies on active systemic treatment.

*Jacob David McGee*

40H #9051-Patient-reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC).

*Virginia Jean Seery*

41A #9052-Impact of the change in service name from "palliative" to "supportive" care on patient referral at a comprehensive cancer center.

*Shalini Dalal, MD*

41B #9053-Pathophysiological role of hormones and cytokines in cancer cachexia.

*Hee-Sook Park*

41C #9054-The cancer survivor survey: Using Web-based technology to assess cancer survivor challenges.

*Ellen M. Lavoie Smith*

41D #9055-Vanderbilt Head and Neck Symptom Survey Version 2.0 (VHNSS 2.0): A tool for the study of long-term oral health consequences of therapy for head and neck cancer (HNC).

*Emily Cooperstein*

41E #9056-Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG).

*Diane C. Bodurka*

41F #9057-Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: Analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs).

*Richard J. Gralla*

41G #9058-The impact of bone health on endocrine treatment strategy in older adults with early-stage, hormone receptor-positive breast cancer.

*Sumanta Kumar Pal*

41H #9059-Expectations of benefit and symptom burdens among advanced cancer patients (ACP) and spousal caregivers during the course of phase I trials.

*Fay J. Hlubocky*

42A #9060-Refinement of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) via cognitive interviewing.

*Jennifer Hay*

42B #9061-Predicting cisplatin-induced ototoxicity in testicular germ cell cancer.

*Jose Gerard Monzon*

42C #9062-Timing of palliative care referral and symptom burden in phase I cancer patients: A retrospective cohort study.

*Henrique Afonseca Parsons*

42D #9063-Evaluation of axillary node dissection on measures of upper-extremity disability and overall quality of life after breast cancer surgery .

*Sarah A. McLaughlin*

42E #9064-Mini-Cog: A brief screening tool for cognitive impairment in older cancer patients.

*Mya S Thein*

42F #9065-Changes in symptoms and inpatient mortality among advanced cancer patients admitted to a palliative care unit in a comprehensive cancer center.

*Masanori Mori, MD*

42G #9066-Retrospective mortality comparisons of cancer patients with sepsis syndromes.

*David Joyce*

42H #9067-Cancer care on a continuum: Maintaining fertility after diagnosis and treatment.

*Jaime Melissa Knopman*

43A #9068-Use of thermal sensation as a biomarker of response to palliative radiotherapy for cancer-induced bone pain.

*Angela C Scott*

43B #9069-An evaluation of health literacy (HL) in a consecutive sample of patients (pts) with cancer (ca) of the head and neck (H+N) region.

*Kelvin Koay*

43C #9070-Innovative quality initiative measurement using Web-based drug dispensing technology with interactive physician queries to evaluate bisphosphonate use across community oncology practices nationwide.

*Cynthia G. Baker*

43D #9071-The associations between spirituality (S), religiosity (R), and spiritual pain (SP) in advanced cancer patients (AdCa).

*Marvin Omar Delgado-Guay, MD*

43E #9072-The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash with cetuximab in cancer patients: A meta-analysis.

*Yevgeniy Balagula, MD*

43F #9073-Use of unnecessary medications by terminally ill cancer patients.

*Rachel Riechelmann*

43G #9074-Polypharmacy in elderly cancer patients.

*Trine Lembrecht Jorgensen, MD*

43H #9075-The association between clinical, sociodemographic, and logistic-administrative factors and adherence to completing health-related quality-of-life questionnaires.

*Jurgen Vercauteren*

44A #9076-Evaluation of variants of the rs1934951 locus of *CYP2C8* and bisphosphonate-related osteonecrosis of the jaw in castrate-resistant prostate cancer (CRPC) patients.

*Paul Gustav Kluetz, MD*

44B #9077-An exploratory analysis of transfusion risk when initiating darbepoetin alfa (DA) therapy at baseline hemoglobin (Hb) < 9 g/dl vs 9 to < 10 g/dl versus  $\geq$  10 g/dl in patients (pts) with chemotherapy-induced anemia (CIA).

*Jean-Luc Re Canon*

44C #9078-Interpretation of do-not-resuscitate (DNR) orders among oncology health care professionals and the potential for these orders to influence care for medical issues unrelated to resuscitation.

*Chad R. Lund*

44D #9079-How accurate is clinician reporting of chemotherapy side effects? A prospective study comparing clinician with patient-reported symptoms.

*Sharmistha Ghosh*

44E #9080-The effect of palliative care consultations on the end-of-life care in the Veteran's cancer population.

*Wilson Gonsalves, Bsc, MD*

44F #9081-Validation of first speech-specific questionnaire for English-speaking head and neck cancer (HNC) patients.

*Rehan Kazi*

44G #9082-Differences in lung cancer clinical trial accrual between a public and university medical oncology clinic.

*Stephen j Vara*

44H #9083-Barriers to symptom management in oncology.

*Betty R. Ferrell, RN, PhD, FAAN*

45A #9084-Uridine triacetate: An orally administered, life-saving antidote for 5-FU overdose.

*Michael K Bamat, PhD*

45B #9085-Differences between old (70-80 years) and very old (80+ years) cancer patients: Results from the IN-GHO registry.

*Friedemann Honecker*

45C #9086-Depression and EGFR mutation status in stage IV non-small cell lung cancer.

*William F. Pirl*

45D #9087-Polypharmacy and functional status in older patients with breast, colon, and lung cancers.

*Gopi K. Prithviraj*

45E #9088-Reactivation of chronic hepatitis B virus in cancer patients receiving immunosuppression: The case for screening.

*Robin B Mendelsohn*

45F #9089-Osteopenia in survivors of childhood cancer.

*Rajaram Nagarajan*

45G #9090-Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care.

*Eva Grunfeld, MD, D.Phil.*

45H #9091-The use of complementary and alternative medicine in patients seen in phase I clinical trials program.

*Saneese Stephen*

46A #9092-Late toxicity and quality of life in oral cavity and oropharyngeal cancer survivors treated with chemoradiotherapy.

*Mafalda Oliveira, MD*

46B #9093-What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860 patient survey in lung, breast, and prostate cancers with implications for drug development.

*Harry Raftopoulos*

46C #9094^-Long-term safety, tolerability, and acceptability of fentanyl pectin nasal spray in the treatment of breakthrough cancer pain.

*Allen W. Burton*

46D #9095-Randomized trial of combined treatment versus usual care plus antidepressant in depressed oncologic patients: One-year follow-up.

*Angela Palao Tarrero*

46E #9096-The prognostic role of quality-of-life assessment in lung cancer.

*Donald Peter Braun*

46F #9097-Predictors of high symptom severity in caregivers of underserved minority cancer patients.

*Guadalupe R. Palos, DrPH*

46G #9098-Correlates and mediators of worry about breast cancer recurrence.

*Nancy K Janz*

46H #9099-Role of yoga in modulating fatigue, sleep disturbances, salivary cortisol, and immune measures in breast cancer survivors: A randomized controlled trial.

*Rao M Raghavendra*

47A #9100-A randomized trial of weekly high-dose calcitriol and weight-bearing exercise for cancer-treatment-induced bone loss (CTIBL) and bone metabolism in ER+ breast cancer (BC) patients.

*Luke Joseph Peppone*

47B #9101-Longitudinal prospective assessment of sleep disturbance in breast cancer.

*Stacy D Sanford*

47C #9102-Clinician perceptions of care difficulty and quality of life for lung cancer patients: Results from the ECOG SOAPP study (E2Z02).

*Heidi A Hamann*

47D #9103-The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy.

*Jason R. Westin, MD*

47E #9104-Pilot evaluation of a stellate ganglion block for the treatment of hot flashes.

*Deirdre R Pachman*

47F #9105-Geriatric assessment in 347 elderly cancer patients: Study of geriatric factors modifying the cancer treatment plan.

*Philippe Caillet*

47G #9106-How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials.

*Belinda Emma Kiely*

47H #9107-Assessing the clinical significance of real-time quality of life (QOL) data in cancer patients treated with radiation therapy.

*Michele Y. Halyard*

48A #9108-Pilot trial of decision aids for patients with advanced breast, lung, colorectal, or prostate cancer.

*Lindsay A Dow*

48B #9109-National survey of U.S. oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by cancer patients.

*Richard T. Lee*

48C #9110-Patient surveillance following curative-intent treatment for breast carcinoma: Current practice patterns.

*Julie A. Margenthaler*

48D #9111-Perspectives on the financial burden of cancer care: Concurrent surveys of patients (Pts), caregivers (CGs), and oncology social workers (OSWs).

*Martin Eichholz, PhD*

48E #9112-Cancer treatment impact on cognitive functioning and quality of life in lung cancer survivors.

*Sadhna Kohli*

48F #9113-A phase II clinical study of interleukin-11 mutein to treat patients with chemotherapy-induced thrombocytopenia.

*Seong-Hyun Ho, DVM*

48G #9114-Can the short screening test vulnerable elders survey 13 (VES-13) substitute for the time-consuming comprehensive geriatric assessment (CGA) to identify vulnerable/frail elderly breast cancer patients?

*Silvio Monfardini*

48H #9115-A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer.

*W. Robert Simons*

49A #9116-A report on the development and validation of first-ever perceptual speech evaluation tool for head and neck cancer (HNC) patients.

*Raghav Dwivedi*

49B #9117-Adolescent and young adult use of Internet-based cancer survivorship care plans.

*Christine E. Hill-Kayser*

49C #9118-Predictors of employment (empl) outcomes in outpatients (pts) with common solid tumors: A secondary analysis from E2Z02 (ECOG's SOAPP study).

*Amye Tevaarwerk*

49D #9119-Enrollment of and toxicity in patients 70 years and older on CTEP/NCI-sponsored, single-agent phase I studies from 1980 to 2005.

*Selina L. Chow*

49E #9120-A prospective evaluation of symptom change over 4 weeks for outpatients with common solid tumors: Results from E2Z02 (the SOAPP study).

*Michael Fisch, MD, MPH*

49F #9121-Prechemotherapy hepatitis B virus (HBV) screening in medical oncology patients: A national survey.

*Fiona Lee Day*

49G #9122-Pregnancy and survival after primary breast carcinoma in young women: A meta-analysis of healthy mother effect studies.

*Davide Mauri*

49H #9123-Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403).

*Florence Joly*

50A #9124-Out-of-pocket (OOP) spending burden for Medicare beneficiaries with cancer.

*Xuehua Ke*

50B #9125-Development of the lymphedema symptoms intensity and distress survey arm.

*Sheila h Ridner*

50D #9127-Chemotherapy-induced nausea and vomiting-associated hospital and ER visits in real-world practice: Palonosetron versus other 5-HT3-RA anti-emetic regimens.

*Hind T Hatoum*

50E #9128-The development and implementation of an institution-based communication skills training program for oncologists.

*Philip A. Bialer*

50F #9129-Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: A phase I study.

*Dawn J Storey*

50G #9130-Activation of the MAP-kinase pathway in the skin of patients treated with sorafenib: Clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib.

*Christine Mateus*

50H #9131-Quality of life (QOL) and cognitive performance among irradiated brain cancer patients.

*Michelle Joy Naughton*

51A #9132-The impact of pharmacotherapy on depression and quality of life in patients undergoing a bone marrow transplant (BMT).

*Patricia B. Mumby*

51B #9133-Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer.

*David H. Henry*

51C #9134-Prevalence of memory problems that limit daily functioning in adult cancer patients: A national representative sample of the U.S. population.

*Pascal Jean-Pierre*

51D #9135-Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1.

*Brandi Reeves*

51E #9136-Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis.

*Amna F Sher*

51F #9137-Prevalence of lymphedema and upper-limb impairments after axillary lymph node dissection or sentinel lymph node dissection in breast cancer: A two-year follow-up study.

*Aase Sagen*

51G #9138-Effect of timing of information on exercise on exercise behavior during cancer treatment: A URCC CCOP protocol.

*Lisa Sprod*

51H #9139-Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB.

*Amanda R Moraska*

52A #9140-Testosterone levels and quality of life (QoL) in male patients with hormone-independent cancers (HIC).

*Stewart Barry Fleishman*

52B #9141-Overall survival in randomized controlled trials of chemotherapy (CT) with or without GCSF support: A systematic review.

*Gary H. Lyman, MD, MPH*

52C #9142-Disparities in receipt of supportive/palliative care services among women with breast cancer.

*Michael T. Halpern*

52D #9143-Post-traumatic stress in patients with acute leukemia.

*Camilla Zimmermann*

52E #9144-Potential plasma biomarkers predicting radiation dermatitis in breast cancer patients.

*Julie L. Ryan*

52F #9145-The impact of symptom clusters on survival in patients with advanced cancer.

*Aynur Aktas, MD*

52G #9146-Use of health-related quality of life and clinical data as prognostic tools for survival prediction in a subgroup of metastatic cancer patients.

*Chantal Quinten*

52H #9147-Effect of GTx-024, a selective androgen receptor modulator (SARM), on stair climb performance and quality of life (QOL) in patients with cancer cachexia.

*Mitchell S. Steiner*

53A #9148-Effect of gabapentin on anxiety among 306 breast cancer patients: A URCC CCOP study.

*Oxana Palesh*

53B #9149-Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib.

*Christine Marie Walko*

54A #9150-Randomized phase II trial of carboplatin (C) and gemcitabine (G) with or without dexamethasone (Dex) in patients (pts) with stage IV non-small cell lung cancer (NSCLC).

*John Joseph Rinehart*

54B #9151-Effect of oral magnesium on hot flashes in breast cancer survivors.

*Haeseong Park*

55A #9152-PROCHE: A program to monitor side effects among patients treated in a medical oncology outpatient unit.

*Florian Scotte*

55B #9153-Cardioprotective effect of telmisartan in cancer patients treated with telmisartan.

*Mariele Dessi'*

55C #9154-Venothromboembolism (VTE) in patients (pts) with acute myelogenous leukemia (AML).

*Nhiem V. Luong, MD, MPH*

55D #9155-Pharmacokinetic study of pegylated liposomal doxorubicin (PLD) in patients over 70: Association with increasing age and cutaneous toxicity.

*Antonio Bononi*

55E #9156-Functional disability and aromatase inhibitor-associated arthralgia in breast cancer survivors.

*Claire F Friedman*

55F #9157-Bone mineral density in childhood cancer survivors (CCS).

*Andrew Charles Dietz*

55G #9158-Venous thrombosis associated with central venous catheter in cancer patients with surgical chest port (S) or venography-guided arm port insertion (R): A randomized controlled study.

*pierre-Yves Marcy*

55H #9159-Coping strategies in young women with breast cancer.

*Kathryn Jean Ruddy*

56A #9160-A practical program for measuring the quality of ambulatory oncology care in the United States: The Quality Oncology Practice Initiative.

*Michael N. Neuss*

56B #9161-Chemotherapy-associated cardiotoxicity: Timeline of left ventricular function recovery on standard heart failure regimen.

*Johannes K Steiner*

56C #9162-Biochemical correlates of fatigue in patients at a comprehensive cancer center.

*Anjali A. Bharne*

56D #9163-Supplemental oxygen for relief of dyspnea in hospice patients.

*Laura Ann Joque*

56E #9164-Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial.

*Giovanni Mantovani*

56F #9165-An analysis of prognostic factors of comprehensive geriatric assessment (CGA) and development of a clinical scoring system in elderly Asian cancer patients.

*Ravindran Kaneshvaran*

56G #9166-Use of a pharmacist/nurse model for the delivery of supportive care in adult oncology clinics at the University of North Carolina Hospital.

*Stephen A. Bernard*

---

**Session Title:** #26: Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our Practice?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** N Hall B1

**Time:** 1:15 PM - 2:30 PM

- The role of neoadjuvant vs adjuvant chemotherapy in pancreatic cancer; what does the data tell us?

*Gauri R. Varadhachary, MD*

- Role of radiation in locally advanced pancreatic cancer

*Theodore Steven Lawrence, MD, PhD*

- Surgical approach in resectable and borderline resectable pancreas cancer

*David Linehan, MD*

---

**Session Title:** #28: Complications of Myeloma and Myeloma Therapies

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E354a

**Time:** 1:15 PM - 2:30 PM

- Prophylaxis of Venous Thromboembolic Disease associated with Immunomodulatory Agents

*Todd M. Zimmerman, MD*

- Prevention and Management of Treatment Induced Peripheral Neuropathy

*Paul Gerard Guy Richardson, MD*

- Myeloma Bone Disease: What's new?

*G. David Roodman, MD, PhD*

**Session Title:** #32: Controversies in the Management of Metastatic Breast Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 1:15 PM - 2:30 PM

- Biological evolution of breast cancer: Should a metastasis be re-biopsed?

*Jonas Bergh, MD, PhD*

- Integration and sequence of systemic options: How to translate clinical trial results into routine practice?

*Cliff Hudis, MD*

- Should cost be a consideration in the management of metastatic breast cancer?

*Michael J. Hassett, MD, MPH*

**Session Title:** #39: Defining Professionalism in Oncology: Current Dilemmas and the Future of the Workforce

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E353

**Time:** 1:15 PM - 2:30 PM

- Medical Professionalism in Historical Perspective

*Robert Martensen, MD, PhD*

- Can we teach professionalism?

*Timothy Jerome Moynihan, MD*

- Professionalism and the oncologist. How professionalism impacts practice.

*David H. Johnson, MD, FACP*

**Session Title:** #49: Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 1:15 PM - 2:30 PM

- Recent advances in endocrine therapy for prostate cancer: new agents, new options

*Mary-Ellen Taplin, MD*

- Where is endocrine therapy going in the next five years?

*Peter Nelson, MD*

---

**Session Title:** #57: Immunoconjugates as Cancer Therapeutics

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100b

**Time:** 1:15 PM - 2:30 PM

- The history and evolution of immunoconjugate treatment as anti- cancer therapy

*Andrew Antony Raubitschek, MD*

- The present state of trials using immunoconjugates targeting solid tumors and new strategies emerging from the lab.

*Raffit Hassan, MD*

- The present state of trials using immunoconjugates targeting lymphoma and heme malignancies and new strategies emerging from the lab.

*Paul A. Hamlin, MD*

---

**Session Title:** #75: NCI Community Cancer Centers Program (NCCCP): A New Paradigm for Clinical Trials in the Community Setting

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S404

**Time:** 1:15 PM - 2:30 PM

- Describe the vision of the NCCCP and its potential impact on community cancer care in the future.

*John E. Niederhuber, MD*

- Multidisciplinary cancer care as the paradigm for prospective case management and clinical trial accrual in the community setting

*Mark Krasna, MD*

- Disparities and community outreach in the NCCCP

*Nicholas J. Petrelli, MD*

**Session Title:** #91: Response-based Therapy: A Personalized Approach to Pediatric Hodgkin Lymphoma

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S504

**Time:** 1:15 PM - 2:30 PM

- Optimizing Chemotherapy: Response and Biology  
*Cindy L. Schwartz, MD*
- RT or not RT, that is the question!  
*Louis S. Constine, MD*
- Functional Imaging and Hodgkin Lymphoma  
*Stephan Voss, MD, PhD*

**Session Title:** #98: The Biology of Leukemia and Myeloproliferative Disorders: Implications for Treatment

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E354b

**Time:** 1:15 PM - 2:30 PM

- JAK 2 and related mutations in myeloid neoplasms. Biology and therapeutic implications  
*Catriona Jamieson, MD, PhD*
- Epigenetic and other rational therapeutic approaches in MPD.  
*Olatoyosi Odenike, MD*
- Micro RNA in AML and CLL. What does it mean?  
*Guido Marcucci, MD*

**Session Title:** #135: Nonglial and Heritable Central Nervous System Tumors

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 1:15 PM - 2:30 PM

- Adult Meningioma: The Evolving Role for Oncologists  
*Marc C. Chamberlain, MD*

**Session Title:** #227: Unraveling the Cancer Genome: Clinical Implications of Next-Generation Technologies

**Session Type:** Clinical Science Symposium

**Date:** Monday, June 7

**Location:** S100a

**Time:** 1:15 PM - 2:45 PM

- Unraveling the Cancer Genome: Clinical Implications of Next-Generation Technologies

*Anil Potti, MD*

- #10500-Massive parallel sequencing of an African-American basal-like breast cancer: Comparison of primary tumor, metastasis, and xenograft.

*Elaine Mardis*

- #10501-Characterization of the microRNAome in a patient with acute myeloid leukemia.

*Giridharan Ramsingh*

- Discussion

*Samuel Aparicio, BM BCh, PHD, MRCPATH*

- #10502-Detection of phosphoinositide-3-kinase, catalytic, and alpha polypeptide (PIK3CA) mutations in matched tissue and plasma samples from patients with metastatic breast cancer.

*Philipp Angenendt, PhD*

- #10503-Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry.

*Carol Beadling*

- Discussion

*Matthew James Ellis, PhD, MB, BCh*

**Session Title:** #262: ASCO/ECCO Joint Session: Personalized Medicine in Locally Advanced Non-small Cell Lung Cancer

**Session Type:** Special Session

**Date:** Monday, June 7

**Location:** E Arie Crown Theater

**Time:** 1:15 PM - 2:30 PM

- Introduction - The Need for Personalized Medicine in Locally Advanced NSCLC

*Michael Baumann, MD*

- Multidisciplinary Localized Therapy □ Innovative Developments in Multidisciplinary Treatments of NSCLC

*Michael Brada, MD*

- Systemic Therapy - What Lies Ahead?

*Jean-Charles Soria, MD, PhD*

- Summary - The Future of Personalized Medicine

*Douglas W. Blayney, MD*

---

**Session Title:** #171: Breast Cancer - Local-Regional and Adjuvant Therapy

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** S403

**Time:** 2:00 PM - 6:00 PM

- Breast Cancer - Local-Regional and Adjuvant Therapy

*Stephen K. L. Chia, MD*

- Breast Cancer - Local-Regional and Adjuvant Therapy

*Lisa Yee, MD*

1 #LBA513-ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.

*Matthew James Ellis, PhD, MB, BCh*

2 #514-Impact of multifocal/multicentric versus unifocal breast cancer on local recurrence.

*Ryan Woods*

3 #515-Determination of clear margin in breast-conserving surgery: Is 1 mm needed?

*Julien Geffrelet*

5 #LBA517-Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: First report of a randomized controlled trial at 10-years maximum follow up.

*Michael Baum*

- Discussion

*Seema Ahsan Khan, MD, FACS, MPH*

6 #518-Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy.

*Michael F. Press*

7 #519-Final results of a meta-analysis testing HER2 and topoisomerase II $\alpha$ ; genes as predictors of incremental benefit from anthracyclines in breast cancer.

*Angelo Di Leo, MD, PhD*

8 #520-Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women.

*Philippe Bedard*

9 #521-Clinically relevant gene signatures in triple-negative and basal-like breast cancer.

*Achim Rody*

10 #522-Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy.

*Sherene Loi*

- Discussion

*Antonio C. Wolff, MD, FACP*

11 #523-First results from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer (EBC).

*Nadia Harbeck*

12 #524-Early discontinuation of tamoxifen and aromatase inhibitors (AIs) by postmenopausal women with early-stage breast cancer.

*John A. Charlson, MD*

14 #526-Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitor-associated arthralgia in breast cancer survivors.

*Jun Mao*

15 #527-Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.

*Karin Ribbi*

16 #528-Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group.

*Lucia Del Mastro*

- Discussion

*Claudine Isaacs, MD*

18 #530-Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).

*Guenther G. Steger*

19 #531-Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC).

*Heikki Joensuu, MD*

- Discussion

*Carlos Caldas, MD, FACP, FRCP, FMedSci*

21 #533-Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer.

*Michael Gnant*

22 #534-Two years of tamoxifen followed by 3 years of anastrozole versus 5 years of tamoxifen alone in postmenopausal women with hormone-responsive early breast cancer: Efficacy results from 3,714 patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 8.

*Peter C. Dubsy, MD*

23 #535-Phase III study of sequential treatment with epirubicin/cyclophosphamide followed by docetaxel compared to FEC120 in the adjuvant treatment of breast cancer patients: The German ADEBAR study.

*Wolfgang Janni*

**Session Title:** #184: Leukemia, Myelodysplasia, and Transplantation

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E450a

**Time:** 2:00 PM - 6:00 PM

- Leukemia, Myelodysplasia, and Transplantation

*Rami S. Komrokji, MD*

- Leukemia, Myelodysplasia, and Transplantation

*Lucy A. Godley, MD, PhD*

1 #6509-Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.

*Carlo Gambacorti-Passerini*

2 #6510-Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib.

*Francis J. Giles*

3 #6511-Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies.

*Moshe Talpaz, MD*

4 #6512-Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.

*Neil P. Shah*

5 #6513-Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib.

*Susan Branford*

6 #6514-Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).

*Hanna Jean Khoury*

- Discussion: Optimizing TKI therapy in advanced CML (Back up speaker is Meir Wetzler at Roswell Park)

*Mier Wetzler, MD, FACP*

7 #6515-Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years.

*Gianantonio Rosti*

8 #6516-Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

*Andreas Hochhaus*

9 #6517-Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg &plusmn; IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV.

*Rudiger Hehlmann*

10 #6518-Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients.

*Amit Roy*

11 #6519-Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).

*Sameer A Parikh*

12 #6520- Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL).

*William Wierda*

13 #6521-Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS).

*Apostolia Tsimberidou*

14 #6522-Phase II trial of daily, oral green tea extract in patients with asymptomatic, Rai stage 0-II chronic lymphocytic leukemia (CLL).

*Tait D. Shanafelt, MD*

15 #6523-Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia.

*Robert J. Kreitman*

- Discussion: Advances in the therapy of chronic lymphoid leukemias

*John C. Byrd, MD*

16 #6524-Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL).

*Carlos Enrique Vigil, MD*

17 #6525-Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.

*Robert K. Stuart*

18 #6526-Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.

*Gail J. Roboz*

19 #6527-Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR).

*Farhad Ravandi Kashani, MD*

20 #6528-A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents.

*Guillermo Garcia-Manero, MD*

- Discussion: Novel therapeutic strategies in MDS and AML

*Harry Paul Erba, MD, PhD*

21 #6529-Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or older) with acute myeloid leukemia (AML) treated with intensive chemotherapy (IC).

*Tapan M. Kadia*

22 #6530-Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients.

*Claude Gardin*

23 #6531-Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies.

*Maria R. Baer*

24 #6532-Treatment of acute myeloid leukemia (AML) in first remission (CR1) with unrelated donor (UD) allogeneic hematopoietic cell transplantation (HCT).

*Qaiser Bashir*

- Discussion: Can management of high risk AML be optimized? (Back up speaker Bob Loewenberg Rotterdam, Netherlands)

*Jane Liesveld, MD*

**Session Title:** #335: Cancer Prevention/Epidemiology

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E450b

**Time:** 2:00 PM - 6:00 PM

- Cancer Prevention/Epidemiology

*Kala Visvanathan, MD, MHS*

- Cancer Prevention/Epidemiology

*Marie Wood, MD*

1 #1509-Impact of early detection strategies on cancer mortality in germline *TP53* mutation carriers in Li-Fraumeni syndrome.

*Anita Villani*

2 #1510-PTEN hamartoma tumor syndrome (PHTS): Clinical characteristics, onco-phenotype, and molecular analysis.

*Mrinal M. Patnaik*

3 #1511-Prevalence of BRCA1 mutations among 284 women with triple-negative breast cancer.

*Florentia Fostira*

4 #1512-Primary fallopian tube lesions in *BRCA* mutation carriers undergoing risk-reducing surgery.

*Fanny Dao*

5 #1513-Noncancer endpoints in *BRCA1/2* carriers after risk-reducing salpingo-oophorectomy.

*Justine Cohen, DO*

6 #1514-Characterization of new Ashkenazi Jewish founder mutations in *MSH6* causing Lynch syndrome.

*Leon Raskin*

7 #1515-What size tumors should we detect as early-stage lung cancers in CT screening? Stage-size relationship in long-term repeated screening over 15 years.

*Nobuhiko Seki*

8 #1516-Assessment of overdiagnosis in CT screening for lung cancer.

*Giulia Veronesi*

9 #1517-Prospective evaluation of whole-body cancer screening with multiple modalities including FDG-PET: Results from annual screening for 5 years in 1,197 healthy volunteers.

*Sadahiko Nishizawa, MD, PhD*

10 #1518-Optically guided surgical approach and the outcome of early-stage oral cancers.

*Catherine F Poh*

12 #1520-Effect of screening on the detection of good and poor prognosis breast cancers.

*Yiwey Shieh*

13 #1521-Phase II randomized placebo-controlled double-blind chemoprevention trial of fruit/vegetable concentrates on intermediate biomarkers in head/neck cancer.

*Edward G. Shaw*

14 #1522-Effect of successful weight loss program on biomarkers for breast cancer in postmenopausal high-risk women.

*Carol J. Fabian*

15 #1523-Role of dietary polyamines in a phase III clinical trial of DFMO and sulindac for prevention of metachronous colorectal adenomas.

*Kavitha P Raj*

16 #1524-Cigarette smoking, fitness, and obesity as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention Trial (BCPT).

*Stephanie R. Land*

17 #1525-Race and colon cancer: Unanswered questions.

*Rajesh Sehgal*

18 #1526-Investigation of ethnic differences in the prevalence of chromosomal number aberrations of luminal and triple-negative breast cancers associated with risk of recurrence.

*Abenaa M. Brewster*

19 #1527-Celecoxib and aromatase activity in breast cancer: Results from a prospective randomized preoperative trial.

*Elisa R. Port*

20 #1528-Evaluation of the potential clinical utility of risk models incorporating genomic risk information.

*Elizabeth Anne Comen*

21 #1529-Integration of specific copy number imbalances and prediction models of early-stage breast cancer recurrence.

*Patricia Thompson*

22 #1530-Nicotinic acetylcholine receptor polymorphism, smoking history, and tobacco-related cancer in the general population.

*Diljit Kaur-Knudsen*

23 #1531-Evaluation of C-reactive protein and YKL-40 as risk factors for incident cancer and early death after a diagnosis of cancer.

*Kristine H. Allin*

24 #1532-Neurocognitive outcomes in adult survivors of childhood Hodgkin lymphoma.

*Neelam Jain*

---

**Session Title:** #6: Acute Leukemia: Integration of Novel Diagnostic and Therapeutic Measures

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E354a

**Time:** 3:00 PM - 4:15 PM

- Molecular/cytogenetic prognostication in AML and its impact on treatment.

*Richard F. Schlenk, MD*

- Upfront and Salvage therapy in AML. What's new?

*Ivana Gojo, MD*

- An update on treatment of adult ALL.

*Anjali S. Advani, MD*

---

**Session Title:** #22: Caring for the Child with Brain Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S504

**Time:** 3:00 PM - 4:15 PM

- High Dose Chemotherapy for Malignant Brain Tumors- What have we learned in the past 2 decades and what does the future hold for this therapy

*Amar J. Gajjar, MD*

- Relapsed Pediatric CNS tumors in 2010 □ strategies and new agents

*Stewart Goldman, MD*

- Understanding Late Effects of Irradiation and Measures to Reduce Dose to Normal Tissue

*Thomas E. Merchant, DO, PhD*

---

**Session Title:** #63: Integrated Considerations in the Management of the Patient with Advanced Ovarian Cancer

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Arie Crown Theater

**Time:** 3:00 PM - 4:15 PM

- Balancing Biologic Behavior with Surgical Therapy

*Andreas Du Bois, MD, PhD*

- The Promise and Toxicity of Novel Targeted Therapies in Ovarian Cancer: Hope or Hype?

*Elise C. Kohn, MD*

- Does Palliative Chemotherapy Palliate? Assessment of Symptom Benefit in Recurrent Ovarian Cancer

*Michael Friedlander, MD, PhD*